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ABSTRACT OF THE DISSERTATION 
THE INFLUENCE OF GENE ENVIRONMENT INTERACTION ON THE RISK OF 
COGNITIVE IMPAIRMENT: REDUCING SEXUAL RISK BEHAVIORS AND 
ALCOHOL USE IN HIV-INFECTED ADULTS 
by 
Karina Villalba 
Florida International University, 2014 
Miami, Florida 
Professor Jessy G. Dévieux, Major Professor 
Memory deficits and executive dysfunction are highly prevalent among HIV-infected 
adults. These conditions can affect their quality of life, antiretroviral adherence, and HIV 
risk behaviors. Several factors have been suggested including the role of genetics in 
relation to HIV disease progression. This dissertation aimed to determine whether genetic 
differences in HIV-infected individuals were correlated with impaired memory, cognitive 
flexibility and executive function and whether cognitive decline moderated alcohol use 
and sexual transmission risk behaviors among HIV-infected alcohol abusers participating 
in an NIH-funded clinical trial comparing the efficacy of the adapted Holistic Health 
Recovery Program (HHRP-A) intervention to a Health Promotion Control (HPC) 
condition in reducing risk behaviors. 
 A total of 267 individuals were genotyped for polymorphisms in the dopamine 
and serotonin gene systems. Results yielded significant associations for TPH2, GALM, 
DRD2 and DRD4 genetic variants with impaired executive function, cognitive flexibility 
and memory. SNPs TPH2 rs4570625 and DRD2 rs6277 showed a risk association with 
viii 
 
executive function (odds ratio = 2.5, p = .02; 3.6, p = .001). GALM rs6741892 was 
associated with impaired memory (odds ratio = 1.9, p = .006). At the six-month follow-
up, HHRP-A participants were less likely to report trading sex for food, drugs and money 
(20.0%) and unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex 
(3.2%) than HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04). Results 
also showed that impaired cognitive flexibility and visual memory were associated with 
increased alcohol use (F = 1, 3.82, η2 = 0.03, p = .05; and F = 1, 5.79, η2 = .05 p = .02), 
respectively. These findings provide evidence that dopamine and serotonin 
polymorphisms influence executive function and memory as well as moderate alcohol 
use and that HHRP-A was effective in reducing sexual transmission risk behaviors in 
HIV-infected alcohol abusers. 
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CHAPTER I 
 
BACKGROUND 
 
A. Introduction 
 
 The development of combination antiretroviral therapy (ART) has mitigated the 
severity of the human immunodeficiency virus (HIV) epidemic. Therapeutic advances 
have transformed HIV/AIDS from a life-threatening illness to a chronic condition.1 
Despite substantial improvements in life expectancy and a lower incidence of HIV-
associated neurocognitive disorders (HAND), neuropsychological and neurocognitive 
deficits continue to be highly prevalent.2 Clinical neurocognitive manifestations of 
HAND in the ART era differ from the typical AIDS dementia complex.1 In the pre-ART 
era, a progressive subcortical dementia with motor and cognitive slowing was common. 
However, today more cortical than subcortical involvement is often reported.3, 4                                         
 The AIDS Task Force of the American Academy of Neurology (AAN) developed 
the Frascati criteria which categorized HAND into three conditions.3 These conditions are 
based on the number of cognitive domains impaired and the level of interference in 
everyday life.  These conditions are asymptomatic neurocognitive impairment (ANI), 
mild neurocognitive disorder (MND) and HIV-associated dementia (HAD).5 Although 
the incidence of HAD has declined, prevalence rates of HAND driven by ANI have 
increased due to increased longevity of affected patients.5 ANI is defined as impairment 
in at least two cognitive domains with one standard deviation below the mean and no 
impairment in activities of daily living.5 Neurocognitive deficits continue to be a 
significant problem in HIV even after the advent of ART.5 High rates of asymptomatic 
neurocognitive disorder have been reported in several recent studies. For example, 
2 
 
Simone and colleagues found that 60% of HIV-positive individuals on ART still suffered 
from some form of neurocognitive impairment.6 Asymptomatic or minimally 
symptomatic neurocognitive disorders are more prevalent in individuals in the current 
ART era than in the pre-ART era.7 An epidemiological study of 1,555 HIV-infected 
adults reported that 33% were diagnosed with ANI, 12% with MND and 2% with HAD.8   
 HAND encompasses a range of cognitive impairments, including slowed 
processing and deficient memory and attention, decreased executive function, and 
behavioral changes, such as apathy or lethargy.9 Although this type of impairment is 
much more subtle than the classic HIV dementia, it still affects daily function, quality of 
life, antiretroviral adherence, and can increase HIV risk behaviors.10 The causes of 
continuing high rates of asymptomatic neurocognitive impairment and, to a lesser degree, 
mild neurocognitive disorder in the ART era are uncertain. However, the variability in 
the penetration of antiretroviral drugs across the blood-brain barrier, neurodegeneration 
caused by toxic inflammatory activation, and lower nadir CD4 T-cell count probably 
contributed to neurocognitive decline. 5, 7, 11, 12 In addition, aging, co-infection with 
hepatitis C, drug abuse, and genetic factors may act as moderators of neurocognitive 
decline.5 Currently, demographic characteristics, medical comorbidities, and lifestyle 
behaviors are used to identify individuals who are at risk for HAND.13 However, 
additional risk factors such as the role of genetics in relation to HIV-susceptibility and 
disease progression should also be examined.10 The accumulated evidence from genetic 
studies suggests that cognition is heritable, leaving some individuals more vulnerable to 
develop neurocognitive disorders than others.14, 15 The contribution of genetic variants 
affecting the metabolism and activity of dopamine and serotonin system genes are known 
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to influence these individual differences.15 Thus, investigating the association between 
dopamine and serotonin-related genetic polymorphisms and neurocognitive decline is 
warranted. This research determined whether specific genetic differences in HIV-infected 
individuals were associated with impaired memory and executive functions, and whether 
cognitive decline moderated alcohol use and sexual transmission risk behaviors. 
Behavioral studies have shown convincing evidence of an intricate association between 
HIV transmission risk behaviors and distal social factors. However, there is not enough 
information on the effects of biological factors on HIV transmission risk behaviors as 
presented below. 
 
   
 
  
 
 
 
 
 
B. Genes Associated with Neurocognitive Disorders  
 Cognitive control processes regulating thought and action are multifaceted 
functions influenced by heritable genetic factors and environmental influences.15 The 
consequences of cognitive impairment are seen by the large range of both neurologic and 
neuropsychiatric disorders that affect the quality of life.10, 16, 17 Cognitive impairment is 
SEROTONIN 
SYSTEM GENES 
1. SLC6A4 
2. GALM 
3. TPH2 
DOPAMINE 
SYSTEM GENES 
1. DRD2 
2. DRD4 
3. ANKK1 
OUTCOMES 
A. Neurocognitive 
Impairment 
OUTCOMES 
B. Sexual Transmission 
Risk Behaviors 
C. Alcohol Use 
 
HHRP-A VS. HPC 
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highly heritable, and individual differences in executive function and memory are 
strongly driven by genetic variations.18 A study by Friedman and colleagues indicated 
that individual differences in executive function including inhibiting dominant responses, 
updating working memory representations, and shifting between task sets, are almost 
99% heritable.19 Additionally, evidence shows that cognition increases linearly from 
childhood to adulthood by genetic modulation of environmental influences on cognitive 
functioning.15 Individuals increasingly select and modify their experiences partly based 
on their genetic predispositions.18, 20, 21 Cognitive neuroscience and pharmacology 
associate dopamine and serotonin as neuromodulators of executive function.15 
Furthermore, studies found associations between serotonin and dopamine polymorphisms 
with sustained attention, memory, and executive function phenotypes in both clinical and 
non-clinical populations.22-25 The most common genes associated with neurocognitive 
impairment are shown in Table 1. 
C. Serotonin Systems 
 Serotonin pathways arise from the dorsal and ventral raphe nuclei to innervate 
cortical and subcortical brain regions, including the limbic forebrain, basal ganglia, 
frontal cortices, thalamus, and the hypothalamus.26 The neurotransmitter serotonin, 5-
hydroxytryptamine (5-HT), is implicated in the pathophysiology of several 
psychological, behavioral, and psychiatric disorders.27 Low 5-HT in the central nervous 
system probably influences impulsivity, aggressive behaviors, increase use of alcohol, 
and risky health behaviors.28 The serotonin transport gene SLC6A4 is one of the most 
extensively studied genes in the serotonergic pathway.22, 29 SLC6A4 encodes the serotonin 
transporter gene that affects serotonergic neurotransmission by reuptake of synaptic 
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serotonin, ending neurotransmission.30 Polymorphisms within SLC6A4 are known to 
influence memory regulation, decision making, and response inhibition.14, 27, 31 In 
addition, twin studies have shown an additive genetic influence on measures of sustained 
attention.32, 33 
 The tryptophan hydroxylase isoform 2, TPH2, is a promising candidate gene for 
cognitive functioning because it is the rate-limiting enzyme of 5-HT synthesis.24 The 
single nucleotide polymorphism (SNP) rs4570625 may lead to increased risk of 
depression, attention-deficit hyperactivity disorder (ADHD), autism, and suicide.34-36 
Evidence of TPH2 gene variations playing a role in cognition comes from studies 
implicating TPH2 in the pathophysiology of ADHD and obsessive-compulsive 
disorder.36-38 A recent study showed that the SNP rs4570625 on TPH2 was associated 
with impaired executive control.39 Another study, on homozygous TT genotype on SNP 
rs4570625, showed low anxiety and high extroversion, indicative of low impulse control, 
which can be correlated to lower prefrontal executive control performance.24 
D. Dopamine Systems 
 Dopamine is a neurotransmitter that regulates functional network activities in 
various regions of the brain. Dopamine neurons are located in the ventral midbrain and 
the diencephalon.40 Dopaminergic neurons send projections to the frontal cortex, globus 
pallidus, striatum, and nucleus accumbens, and are involved in several cognitive 
functions influencing performance, motor control, reward, and cognition.41, 42  Dopamine 
and serotonin systems modulate executive function by co-jointly adjusting neurochemical 
transmission in the prefrontal cortex (PFC).15 The PFC plays a central role in top-down 
control of many higher-order executive tasks. It is involved in learning, memory, 
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categorization, inhibition control, and cognitive flexibility.43-45 Activation of D1, D2, D3, 
and D4 receptors modulate the excitability of receptor cells and PFC neural network 
activity. 46 The dopamine D2 receptor gene, DRD2, is one of the most extensively 
investigated genes associated with dopamine receptor function, with the TaqIA 
polymorphism being the most frequently studied.46, 47 The D2 receptor of the DRD2 gene 
is associated with PFC mediated behaviors including attentional control, planning, and 
verbal reasoning.47 Other areas include visuospatial performance and cognitive  
flexibility.48 
 The dopamine D4 receptor is widely expressed in the CNS, particularly in the 
frontal cortex, hippocampus, amygdala and hypothalamus.33, 49 The DRD4 gene is located 
on chromosome 11p15.5 and has a highly variable number of tandem repeats (VNTR) in 
the coding sequence.23, 50 The three most common polymorphic variants of the receptor in 
the human population are D4.4, D4.7 and D4.2. However, they are functionally and 
pharmacologically nearly indistinguishable from each other.51, 52 Individuals with D4.7 or 
more repeats show both reduced binding affinities and receptor densities for dopamine 
neurotransmission.53 Several studies have analyzed the association between the D4.7-
repeat allele in DRD4 gene and ADHD.23, 33 The D4.7 repeat correlates with impulsivity 
and lower levels of response inhibition.54 Table 2 shows significant associations found in 
the literature and relevant to this review.  
E. HIV-associated Pathologies in Dopamine and Serotonin Systems 
 HIV neuropathology is widespread in both the cortical and subcortical brain 
regions.13 HIV enters the CNS through infected macrophages/monocytes early in the 
course of infection and the virus resides primarily in microglia and macrophages.55 
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Microglia and macrophages are the only resident CNS cells capable of increasing HIV 
infection in the brain.56 The infection of these cells leads to a cascade of neurotoxic 
events that damage neurons through the production of secreted viral neurotoxins, 
neuroinflammation, myelin degradation, and the breakdown of the blood-brain barrier.57 
HIV-related neuropathology is particularly prevalent in areas of the frontal lobes and 
subcortical structures, especially the putamen and caudate nuclei, the hippocampus, basal 
ganglia and substantia nigra.2, 58, 59 Specifically, there is a significant decrease in the 
levels of homovanillic acid in the cerebrospinal fluid of AIDS patients, results that are 
probably related to loss of dopamine cell bodies in post-mortem tissues of these 
patients.60 
F. HIV-associated Neurocognitive Disorders 
 Behavior encompasses three functional systems: cognition, emotionality, and 
executive function.61 HIV infection can disrupt all three of these functional systems.5 
Cognition is the ability to select, classify, and integrate information. It also includes 
information storage, retrieval, mental organization, and recognition of information.61 
Executive function is part of a system that acts in a supervisory capacity of the brain 
through planning, decision-making, and response control for purposeful goal-directed 
behavior. 62 Memory is a subclass of cognitive function, divided into long-term and short-
term (working) memory. Long-term memory is further divided into explicit and implicit 
memory as shown in Figure 1.63 Neuropsychological studies have shown an association 
between HIV-associated neurocognitive impairment and dysfunction of frontostriatal 
circuits that mediate processing speed, working memory, and executive function.64-66 For 
example, these patients suffer from impairment of episodic memory and visual memory, 
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as well as affective and cognitive-emotional processing.67 Other studies have documented 
limited use of higher level encoding strategies, such as semantic clustering and strategic 
retrieval that may negatively impact medication adherence and cause poor work-related 
performance.68, 69 Normal executive function is dependent on the structural and functional 
integrity of the dorsolateral parietal cortex.70 Executive dysfunction and poor cognitive 
flexibility are the most prevalent neurocognitive impairment among HIV-infected 
adults.71-73 Risky decision making is also affected by HIV infection that can impact 
frontostriatal circuits and subcortical regions.74 For example, HIV-infected adults have 
the propensity to choose larger immediate rewards over gradually-accumulated smaller 
rewards that result in overall long-term gains.74 These observations suggest that HIV-
infected adults make more impulsive and risky decisions in their daily lives (e.g., failure 
to use a condom).5 
G. HIV-associated Risky Behaviors 
 Recent studies suggest that, in addition to opiates, cocaine, and 
methamphetamine, alcohol, cannabinoids, and tobacco may also influence the effects of 
HIV on the brain.75 HIV-infected substance abusers are more prone to rapid progressive 
illness with higher viral loads, decreased immune suppression, and increased cognitive 
impairments compared to HIV-infected non-substance abusers.76 In addition, an 
established trend of high-risk behaviors, often associated with depression is observed in 
this population.77 HIV-infected substance abusers are more likely to be non-adherent with 
antiretroviral medication, a factor that may account for worsening cognitive function, and 
more rapid disease progression.78        
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There is a high level of comorbidity of alcohol dependence and HIV infection.79, 
80 For example, the rate of heavy drinking among HIV-infected adults is almost twice that 
of the general public.81 HIV-infected individuals who abused alcohol showed a nine fold 
increase in medication noncompliance compared to HIV-infected non-alcohol abusers.82 
Chronic alcohol use is characterized by compulsive and obsessive behaviors which can 
negatively activate the mesolimbic dopamine reward system and influence the effects of 
serotonin in the brain.83, 84 Abnormal dopaminergic transmission is considered one of the 
pathogenic mechanisms of alcohol dependence.85 Dopamine is thought to mediate reward 
mechanisms in mesolimbic neurons and numerous studies have focused on genes related 
to dopamine function.41, 46 In contrast, the serotonergic system is believed to modulate 
alcohol craving and drinking behavior.86 Alcohol exposure alters several aspects of 
serotonergic signal transmission in the brain.87  
 The effects of chronic alcohol use on cognitive function are greater for current 
consumption, higher quantities, longer duration, and older age.82 A clinical study 
evaluated the effect of regular daily consumption of six or seven standard alcoholic 
drinks and found a moderate association with cognitive impairment.88 Clinical studies 
show that not all chronic drinkers are at equal risk for brain changes; most suffered mild 
cognitive impairment which can improve within a year of abstinence.89, 90 Findings on the 
effects of alcohol abuse and HIV infection are mixed. Some studies have demonstrated 
that alcohol abuse and HIV infection have independent effects on cognitive function91, 92 
while others have proposed the possibility of increased vulnerability to cognitive 
impairment due to an interaction between chronic alcohol use and HIV infection.79, 93 
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Although healthcare practitioners have turned to antiretroviral therapies to avert 
new infections and to slow down HIV disease progression, alcohol can pose a serious 
challenge to HIV treatment and prevention.94 Furthermore, alcohol may interfere with the 
prevention of HIV transmission by impeding ART adherence and increasing the risk for 
sexual risk behaviors.95 Heavy alcohol consumption impairs judgment and cognition 
which in turn diminishes the perception of risk, leading to unsafe sexual practices and 
increased risk of HIV transmission.96 Furthermore, one in three HIV-infected alcohol 
abusers engaged in unprotected vaginal or anal intercourse with an uninfected partner in 
the last year.94 A meta-analysis assessing the association between alcohol and 
unprotected sex, based on diverse indicators of alcohol consumption (global, situational 
and event-level), showed significant associations with alcohol use and unsafe sexual 
practices.98 
 Intervention studies focusing on alcohol use are important due to the wide 
spectrum of problems associated with sexual transmission risk and antiretroviral 
adherence among HIV-infected individuals.99 In general, behavioral interventions are 
designed to improve HIV treatment adherence and to reduce unsafe sexual practices. 
Evidence shows that risk reduction interventions are more effective for participants who 
are not chronic alcohol users.100, 101 Alcohol use threatens the success of intervention and 
prevention programs and should be addressed when developing programs for HIV-
infected individuals.                                                
H. Significance 
 Asymptomatic neurocognitive impairment remains a challenge during the ART 
era.1 Memory deficits and executive dysfunction are highly prevalent among HIV-
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infected adults.8 These conditions can affect their quality of life, antiretroviral adherence, 
and HIV risk behaviors.5 The causes of asymptomatic neurocognitive impairment are still 
unclear. However, several factors have been suggested including the role of genetics in 
relation to HIV disease progression.5 It is suggested that among HIV-infected adults who 
suffer from impaired cognition, genetically determined polymorphisms in dopamine and 
serotonin-related genes, may amplify differences in cognitive performance measures 
compared to healthy subjects. Cognitive functions are influenced by the serotonin and 
dopamine systems. Thus, genetic differences in the serotonin and dopamine system genes 
may exacerbate the development of neurocognitive impairment in an individual.1, 5, 15   
 Behavioral studies have shown evidence of an intricate association between HIV 
transmission risk behaviors and distal social factors. However, there is not enough 
information on the effects of biological factors on HIV transmission risk behaviors. This 
dissertation hypothesizes that serotonin and dopamine-related gene polymorphisms 
compounds the HIV-associated vulnerability to deficits in executive function, cognitive 
flexibility and memory and these cognitive impairments moderate alcohol use and sexual 
transmission risk behaviors.  
I. Statement of Aims and Hypotheses                                                                 
Specific Aim 1: To investigate whether serotonin-related polymorphisms (SLC6A4 5-
HTTLPR, TPH2 rs4570625 and GALM rs6741892) are associated with impaired 
executive function and memory.  
 Hypothesis 1: Serotonin-related polymorphisms are associated with impaired 
executive function and memory in HIV-infected alcohol abusers. 
Specific Aim 2: To investigate whether dopamine-related polymorphisms (DRD4 D4, 
12 
 
ANKK1 rs800461, and DRD2 rs6277) are associated with impaired cognitive flexibility 
and executive function. 
 Hypothesis 2: Dopamine-related polymorphisms are associated with impaired 
cognitive flexibility and executive function in HIV-infected alcohol abusers. 
Specific Aim 3: To evaluate the effectiveness of the adapted Holistic Health Recovery 
Program (HHRP-A) on reducing alcohol use and HIV sexual transmission risk and to 
explore whether cognitive impairment moderates alcohol use and sexual transmission 
risk.   
 Hypothesis 3A: Participants in the experimental group will show a greater 
reduction in alcohol use and sexual transmission risk than participants in the 
comparison group. 
 Hypothesis 3B: Cognitive impairment moderates alcohol use and sexual 
transmission risk in HIV-infected alcohol abusers. 
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Table 1. Serotonin-and dopamine-related genes associated with cognitive functions 
 
 
 
5-HT, serotonin; SLC6A4, serotonin transporter; DA, dopamine; DAT1, dopamine transporter 1; DRD2: 
dopamine receptor D2; DRD4, dopamine receptor D4; fMRI: functional magnetic resonance imaging;  
SNP, single nucleotide polymorphism; TPH, tryptophan hydroxylase; VNTR, variable number tandem 
repeat. 
 
 
 
 
 
 
 
 
 
 
 
Neurotransmi
tter Gene 
Genetic 
variant 
Molecular 
association 
Cognitive 
test 
Cognitive 
association 
Dopamine DRD4 VNTR exon 3 
7-repeat allele 
associated with 
decreased dopamine 
ability to inhibit camp 
formation 
Go/NoGo 
task 
4-repeat allele 
showed less 
accurate response 
inhibition 
Dopamine DRD4 VNTR exon 3 
7-repeat allele 
associated with 
decreased dopamine 
ability to inhibit 
cAMP formation 
Stop-signal 
task 
Adults with the 7-
repeat allele 
displayed impaired 
inhibition 
Serotonin TPH2 rs4570625 
TPH associated with 
regulation of 
serotonin availability 
fMRI image 
test 
T allele associated 
with impaired 
executive control 
Serotonin TPH2 rs4570625 
TPH associated with 
regulation of 
serotonin availability 
Working 
memory task 
G allele associated 
with fewer errors  
Serotonin SLC6A4 
5HTTLP
R 
L allele associated 
with increased 5-HT 
uptake compared to S 
allele 
Continuous 
performance 
task 
L allele associated 
with higher rates of 
omission and 
commission rates  
Serotonin SLC6A4 
5HTTLP
R 
L allele associated 
with increased 5-HT 
uptake compared to S 
allele 
Working 
memory task 
S/S genotype 
associated with 
higher error-rate 
performance  
Serotonin SLC6A4 
VNTR 
intron2 
STin2-polymorphisms 
as transcriptional 
regulators 
Trial making 
test, Rey 
auditory 
verbal 
learning test 
Homozygous 
STin2.10 associated 
to cognitive 
dysfunction in 
depressed adults 
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Table 2. Characteristics of the most studied SNPs associated with the risk of cognitive 
decline and dementia 
 
  
       *Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide 
 position (http://www.ncbi.nlm.nih.gov/SNP/) 
 **PMID PubMed Identification Number  
 
 
 
 
  
Chromosome 
nucleotide 
position 
Gene Genotype MAF* SNP-risk allele PMID** 
Chr.19:44892362 TOMM40 A/G G = 0.1336 rs2075650 23207651102
Chr. 8:65732478 MTFR1 A/G G = 0.3641 rs10808746 23535033102
Chr. 19:44906745 APOE A/G A = 0.0822 rs769449 24468470103
Chr. 2:127137039 BIN1 C/T G = 0.3714 rs744373 19734903103
Chr. 6:47484534 CD2AP C/T C = 0.1905 rs9296559 21460840103
Chr. 6:129476939 LAMA2 C/T C = 0.2461 rs2571577 23535033104
Chr. 13:85634269 SLC8A1 C/T C = 0.1322 rs9602785 23535033104
Chr. 13:85634269 SLTRK6 C/T C = 0.1322 rs9602785 23535033104
Chr. 21:45621894 PCBP3 G/T T = 0.1538 rs11701130 23535033105
Chr. 7:143412046 EPHA1 C/T C = 0.1878 rs11767557 21460840105
Chr. 2:136957689 PICALM A/G T = 0.3297 rs3851179 19734902106
Chr. 2:136957689 THSD7B C/T C = 0.3880 rs524398 23535033106
Chr. 8:27607002 CLU C/T T = 0.3848 rs11136000 19734902106
Chr. 1:207518704 CR1 A/G A = 0.0877 rs6656401 19734903107
Chr. 19:51224706 CD33 G/T A = 0.2378 rs3865444 21460840107
Chr. 11:6013029 OR56A1 C/T C = 0.2195 rs10769565 23535033107
Chr. 5:11043805 CTNND2 A/T T = 0.3030 rs2973488 23535033108
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Figure 1. Types of human memory   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human Memory
Sensory Memory Short-term Memory 
(working memory) 
Long-term Memory 
(lifetime) 
Episodic Memory 
(events, experiences) 
Semantic Memory 
(facts, concepts) 
Procedural 
Memory (skills, 
tasks)
Declarative Memory 
(facts, events) 
Implicit 
Memory 
Explicit Memory 
(conscious) 
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CHAPTER II. METHODS 
A. Data Source 
  Data collected from the study entitled "Intervening with HIV+ Alcohol Abusers: 
Influence of Neuro-Behavioral Factors" were used to examine the research aims in this 
dissertation. The main study was a longitudinal (12 month follow-up) randomized 
controlled trial designed to reduce HIV sexual transmission risk and substance use, 
increase the utilization of primary HIV care services and to improve psychosocial health 
among a sample of HIV-infected alcohol abusers.  
 The experimental condition was an adaptation of the Holistic Health Recovery 
Program (HHRP), an evidence-based intervention guided by the Information-Motivation-
Behavioral skills (IMB) model.1 The HHRP program was originally designed for drug 
abusing populations (See Appendix 1).2 However, the main study from which this 
dissertation is derived, used and adapted version (HHRP-A) of the original evidence-
based intervention specifically tailored for alcohol abusing populations. 
1. Recruitment and Informed Consent 
 Recruitment was conducted in multicultural, low income, urban areas of Miami-
Dade County. These areas are known for their high rates of alcohol and other drugs of 
abuse, HIV, poverty and lack of health insurance. Thirteen community-based 
organizations (CBOs) serving the target population agreed to act as recruitment sites. 
These CBOs were among the largest in Miami-Dade providing outpatient treatment 
programs for alcohol and other drugs of abuse and mental health services to HIV-positive 
men and women. Recruiters screened interested potential participants to determine 
eligibility and proceeded to the informed consent process if all eligibility criteria were 
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met. The recruiter met each potential participant in a private space and explained the 
study procedures, the intervention and assessment protocols, the follow-up periods, the 
confidentiality and compensation. A separate consent form was presented to eligible 
participants to solicit their participation in the genetic testing and blood draw. They were 
informed that they could decline to participate in the intervention study or the blood draw 
and withdraw at any time without adverse consequences.  
 Since this study collected highly sensitive clinical data, multiple layers of 
protection for confidentiality were developed: First, a Data Safety Monitoring Board was 
established for this project. Second, only the participant’s number was used on the data 
collected thus, making it impossible to link a specific participant to questionnaire and 
genotype data collected. Only the Principal Investigator and project coordinator had 
access to the password protected and encrypted database linking participants’ names and 
numbers. Finally, a Certificate of Confidentiality was obtained from the National Institute 
on Alcohol Abuse and Alcoholism. 
 The inclusion criteria were: between 18 and 60 years old, HIV-positive and 
willing to present documentation to confirm serostatus, consumed alcohol in the last 3 
months with a history of alcohol abuse or dependence within the past 2 years, and at least 
one episode of unprotected vaginal or anal sex in the past 90 days. Additional criteria 
included: ability to understand and speak English, ability to understand the informed 
consent, and ability to provide contact information to facilitate being located for follow-
up interviews.  Other inclusion criteria included willingness to be randomized to the 
experimental or control group, not facing immediate incarceration or residence in a 
restricted environment, and currently not showing overt signs of major psychiatric 
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disorder. As previously mentioned, blood specimen collection for the study was optional 
and subject to informed consent.  See appendix 2 for further information on the CBOs. 
2. Group Randomization 
 Once participants completed the baseline assessment, they were entered into the 
study in groups of eight of the same sex. The groups of participants were assigned to 
receive either the experimental or control condition, using a randomized block design, 
based on a computer-generated random sequence assignment. Random sequencing was 
used to control for bias in subject assignments across conditions. To prevent cross-group 
contamination participants were recruited from different locations. Each cohort was 
staggered in time to reduce the possibility of interaction and to prevent discussion of their 
experiences with participants from different cohorts. 
3. Treatment Condition: HHRP-A 
 HHRP is an evidence-based program designed to promote risk reduction 
behaviors among  HIV-positive individuals.2 While the original intervention (HHRP) 
included twelve weekly group sessions, the adapted intervention (HHRP-A) included 
eight, two-hour sessions, delivered twice a week, for four weeks. Some of the topics 
discussed were: setting and reaching goals, reducing risk behaviors, preventing relapse, 
adherence to antiretroviral treatment, and coping with stigma and grief. There was an 
emphasis on relaxation and coping skills training designed to reduce negative mood, and 
build positive social support networks with peers. Cognitive remediation strategies were 
incorporated because of the potential for cognitive impairment in this population. Some 
of these strategies were repetition and review, behavioral games, memory books, 
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reduction of distraction and fatigue, as well as an ongoing assessment of learned 
materials with immediate feedback.3 
4. Treatment Condition: Health Promotion Comparison 
 The Health Promotion Comparison (HPC) condition focused on educational and 
didactic methodologies, addressing common health problems such as nutrition, physical 
fitness, smoking avoidance/cessation and healthy living. HPC did not incorporate 
behavioral skills training or motivational enhancement techniques. HPC matched HHRP-
A in total administration time and format (eight, two-hour sessions). However, the 
program was condensed and delivered in two days, to reduce the risk of cross-group 
contamination and the potential for enhancing social support that group sessions repeated 
over time could engender. A session offering standard care of HIV education was 
included in the HPC program. It was unethical not to include an HIV education in the 
comparison group, given the high-risk nature of this population.  
B. Materials 
1. Selection of Genetic Markers 
 A group of genetic markers known to correlate with cognitive function was used. 
Serotonin-and dopamine-related genes were selected using the medical literature which 
was reviewed for associations with cognitive function.4-7 The following genes were: 1) 
solute carrier family 6 (neurotransmitter transporter, serotonin), 2) member 4 (SLC6A4), 
3) dopamine receptor D2 (DRD2), 3) dopamine receptor D4 (DRD4), 4) galactose 
mutarose , aldose 1-epimerase (GALM), 5) solute carrier family 6 (neurotransmitter 
transporter, dopamine) member 3 (SLC6A3),  6) ankyrin repeat and kinase, domain 
containing 1(ANKK1) and 7) tryptophan hydroxylase isoform 2 (TPH2). 8-15 The chosen 
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polymorphisms were further divided into two categories: single nucleotide 
polymorphisms (SNPs) and variable number tandem repeats (VNTR). A SNP is a single 
nucleotide change in the DNA sequence code.16 It is the most common type of stable 
genetic variation and is bi-allelic.16 VNTR is a linear arrangement of multiple copies of 
short repeated DNA sequences that vary in length and are highly polymorphic, making 
them useful as markers in genetic analysis.17 Tables 1and 2 include characteristics of the 
genetic polymorphisms that were analyzed.  
2. Genotyping 
 Genotyping was done by TaqMan® SNP Genotyping Assays (Foster City, CA, 
USA) using the Bio-Rad CFX96™ System. Genotyping was performed blindly, without 
knowledge of the clinical status of the participants. Data acquisition and analysis were 
done on Bio-Rad CFX manager software (2.1). The detection method for allelic 
discrimination was based on changes in fluorescence. Usually, the software assigns 
specific dye fluorescence to each of the two alleles amplified, HEX-dye and FAM-dye. If 
only one dye shows fluorescence then it is indicative of homozygosity. If both dyes are 
detected, it is indicative of heterozygosity. Life Technologies provided data on which 
allele was labeled by which dye, typically HEX (allele 1) is the major allele, and FAM 
(allele 2) is the minor allele. VNTR variants were analyzed using conventional PCR. The 
primers were from (Integrated DNA Technologies (IDT) Coraville, Iowa, USA). The 
online IDT SciTools software Oligo Analyzer 3.0 (www.idtdna.com) was used for primer 
validation. The cycling conditions for the PCR process was optimized for each template 
and primer pair combination. The amplicons were run on an agarose gel with an 
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appropriate molecular weight marker for size determination. For protocol details and 
genetic terminology used in this dissertation see Appendices 3 and 4. 
 Viral load and CD4+ T cell count came from the documentation collected by the 
participant’s own health care provider within one month from study intake; this 
information was provided by the participant at baseline. Demographic characteristics 
were also collected. Timeline Followback (TLFB) assessed sexual transmission risk, 
alcohol use and other drugs. The Alcohol Use Identification Disorder Test (AUDIT) 
determined alcohol use severity. Neurocognitive impairment was assessed by the 
following neurological tests: The Rey-Osterrieth Complex Figure, Short Category, Color 
Trail A and B, and Auditory Verbal Learning. 
3. Neurocognitive Measures 
 The Rey-Osterrieth Complex Figure Test:  It is a widely used measure for 
visuospatial construction and nonverbal memory.18 It consists of a complex geometric 
figure that is copied and then redrawn from memory. Accuracy of correctly copied or 
recalled elements is measured based on a score from 0 to 36. The figure is divided into 18 
components. Each piece is evaluated with respect to its drawing accuracy.19 This 
instrument shows high test-retest reliability, with alpha scores for copy accuracy as 0.88 
and for recall as 0.87.20 
 Auditory Verbal Learning Test: This test measures verbal memory capacity, 
retrieval efficiency, and learning.21 The assessment is based on a five-trial presentation of 
a 15-noun word list (list A) with a presentation rate of one word per second. A free recall 
test follows each trial. On completion of trial 5, a single word presentation of a 15-noun 
word interference list (list B) is presented. The test measures total learning, learning rate, 
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interference measures, retention measures, and recognition measures with lower scores  
indicative of greater impairment.22 This instrument demonstrates high test-retest 
reliability, with alpha scores ranging from 0.51 to 0.72.23 
 Color Trails 1 Form A and B:  The CTT is based on the use of numbered colored 
circles and universal sign language symbols.24 Trail A requires the individual to connect 
colored circles numbered 1-25 as fast as possible using a pencil. Trail B requires the 
individual to alternate between pink and yellow colored circles numbered 2-25 as fast as 
possible. The test measures the time to completion, errors, near misses and prompts.25 
Trail A evaluates sustained visual attention while Trail B evaluates cognitive flexibility 
The test uses the time in seconds the participant needs to complete the test, with higher 
scores indicating poorer functioning.24 This instrument demonstrates high test-retest 
reliability, with alpha scores ranging from 0.85 to 1.00.24 
 The Category Test Short Form-Booklet Format: The SCT assessment consists of 
five booklets, one for each subtest, with 20 cards per subtest. All of the cards within each 
subtest are organized according to a single principle. Thus, the test requires the individual 
to formulate an organizing concept for each subtest. The number of errors on each 
booklet is added and translated to normalized T-scores. Impairment is determined by 
higher scores indicating poorer functioning.26 Test-retest coefficients range is from 0.60 
to 0.96 depending upon the severity of impairment in the sample.27 
4. Sexual Risk Behavior and Alcohol Use Measures 
 Degree of Alcohol Use Severity: AUDIT is used to measure alcohol use patterns.  
The AUDIT is a 10-item survey that measures alcohol consumption, dependence 
symptoms and personal and social harm reflective of drinking over the past 30 days.28 
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The AUDIT score measures low-risk alcohol level from 0 to 7; high-risk alcohol level 
from 8 to 15; harmful alcohol level from 16 to 19; and probably dependency level ≥ 20.28 
 Timeline Followback: The TLFB is a method used to obtain estimates of daily 
drinking and sexual behavior.29 It uses a calendar format which helps determine 
retrospective estimates of the participant's daily drinking and sexual events over the last 
three months.29 TLFB was developed originally to assess alcohol use, using memory aids 
to enhance recall (e.g., key dates serve as anchors for reporting drinking). This method 
provides a wide range of information including pattern, variability, and the magnitude of 
drinking.30 TLFB is also used for sexual behavior. The structure of the TLFB encourages 
an interactive process whereby memory of one event may facilitate recall of similar or 
related events.31 In addition, the TLFB method permits interviewers to obtain enriched 
contextual information regarding risk behavior. This ability to provide detailed event-
level data is especially important for research on the co-occurrence of risky behaviors. 
Test-retest intraclass correlations from the TLFB showed that all sexual behaviors are 
reliable, ranging from .86 to .97.31 
C. Analysis 
 To standardize cognitive measures, standardized T-scores were developed by 
using multiple linear regression methods analyzing the influence of age, sex, education, 
and ethnicity on each cognitive test score. These standardized T-scores were used to 
determine cognitive impairment according to the Frascati criteria,32 presented in Table 3.  
 Data were evaluated for potential selection bias since 112 participants did not 
participate in this study. Statistical analyses were performed using Stata v.11 (StataCorp, 
College Station, TX). Logistic and linear regression were used to explore the associations 
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between dopamine and serotonin-related genes and cognitive impairment (executive 
functioning, cognitive flexibility, memory and visual memory). The statistical threshold 
was set at P < .05 and 95% confidence intervals (CIs). Ethnic and gender -specific 
associations were calculated through stratified analyses. Genotyping counts were tested 
for Hardy-Weinberg equilibrium (HWE) for each SNP. Associations in the overall 
sample were assessed by adjusting for sex and ethnicity. By default, the additive genetic 
model was used but the use of the dominant and recessive models was considered.  
 Data for alcohol use were transformed using the Box-Cox method.33 Data for 
sexual transmission risk were analyzed using nonparametric methods. Initially, the 
Wilcoxon signed-rank test was used for all the analyses. Transformed data used the t-test 
and ANOVA methods to measure the outcomes. Change over time on continuous 
measures was analyzed using two repeated measures analysis of variance (ANOVAs) for 
treatment condition and time variables. Where change over time in any continuous 
variable was detected, effect sizes (partial η2) were reported. Intervention outcomes were 
assessed by alcohol use and sexual transmission risk. The outcomes were modeled as a 
function of condition (intervention or control), time (baseline and follow-up), gender, and 
condition by time interaction. The interaction between neurocognitive measures and 
alcohol was also measured.  
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Table 1: Variable number tandem repeats analyzed in the study 
bp = base pair 
 
   
 
 
 
Table 2: Single nucleotide polymorphisms analyzed in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymorphism Gene Symbol Gene Name Chromosome VNTR Type 
5HHTLPR SLC6A4 Solute carrier family 6, member 4 17 44bp insertion/deletion 
STin2 SLC6A4 Solute carrier family 6, member 4 17 
17 bp tandem repeat,  
9,10 and 12 copies 
DAT SLC6A3 Solute carrier family 6, member 3 5 
40 bp, tandem repeat, 3 
to 11 copies 
D4 DRD4 Dopamine receptor D4 11 
48 bp tandem 
repeat, 2 to 10 
copies 
Ref-SNP ID Gene Symbol Gene Name Chromosome SNP Type 
Rs800461 ANKK1 Ankyrin repeat and kinase domain containing 1 11 
Amino acid 
substitution 
Rs6277 DRD2 Dopamine receptor D2 11 Amino acid substitution 
Rs6741892 GALM Galactose mutarotase aldose 1-epimerase 2 Missense 
Rs4570625 TPH2 Tryptophan hydroxylase isoform 2 12 5' upstream 
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Table 3. Categories of HIV-associated neurocognitive disorder according to Frascati 
criteria 
 
 Neurocognitive status* Functional status** 
Asymptomatic neurocognitive 
impairment 
1 SD below the mean in   
2 cognitive domains 
No impairment in activities of 
daily living 
Mild neurocognitive impairment 
or disorder 
1 SD  below the mean in  
2 cognitive domains 
Impairment in activities of daily 
living 
HIV-associated dementia 2 SD below the mean in  2 cognitive domains 
Notable impairment in activities 
of daily living 
 
SD=standard deviation. 
 
 *Neurocognitive testing should include an assessment of at least five domains, including attention–
information processing, language, abstraction-executive, complex perceptual motor skills, memory 
(including learning and recall), simple motor skills, or sensory, perceptual skills.  
 
**No agreed measures exist for HIV-associated neurocognitive disorder criteria.  
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CHAPTER III 
SEROTONIN-RELATED GENE POLYMORPHISMS AND ASYMPTOMATIC 
NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED ALCOHOL ABUSERS 
 
A. Abstract 
 Memory deficits and executive dysfunction are highly prevalent among HIV-
infected adults. These conditions can affect their quality of life, antiretroviral adherence 
and HIV risk-taking behaviors. Cognitive impairment is highly heritable and individual 
differences in executive function and memory are strongly driven by genetic variations. 
There is strong evidence from cognitive neuroscience associating dopamine as a 
neuromodulator of executive function. However, the role of the 5-hydroxytryptamine (5-
HT) system, in cognition is less clear. The aim of this study was to investigate the 
potential associations between single nucleotide polymorphisms (SNPs) in the serotonin 
system genes and cognitive impairments in HIV-infected adults. A total of 267 
biologically unrelated individuals were genotyped for polymorphisms SLC6A4 5-
HTTLPR, TPH2 rs4570625 and GALM rs6741892. To assess neurocognitive functions, 
the Short Category, the Color Trails, and the Auditory Verbal Learning tests were used. 
Results yielded statistically significant associations for TPH2 and GALM variants with 
impaired executive function and memory. The SNP rs4570625 showed a significant 
association with impaired executive function (odds ratio = 2.5, 95% CI, 1.1-4.9; p = .02). 
The risk increased in African American males (odds ratio = 4.8, 95% CI, 1.5-14.8;           
p = .005). SNP rs6741892 was associated with impaired memory (odds ratio = 1.9, 95% 
CI, 1.2 - 3.1; p = .006), and again the risk increased in African American males (odds 
ratio = 2.4, 95% CI, 1.2-4.9; p = .02). No significant associations were seen with the 5-
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HTTLPR polymorphism. Findings in this study suggest that TPH2 rs4570625 and GALM 
rs6741892 polymorphisms in the serotonin system influence cognitive control in HIV-
infected alcohol abusers. 
B. Introduction 
 The development of ART has drastically improved HIV survival rates in the past 
few decades.1 However, HIV-associated neurocognitive disorders remain highly 
prevalent and continue to represent a significant public health problem.2 While the 
incidence of HIV-associated dementia has declined in the ART era, around 50% of HIV-
infected individuals will continue to experience some form of neurocognitive decline. 
With the most prominent decline on deficient memory and attention, decreased executive 
function, and behavioral changes such as apathy or lethargy.1, 3 Executive function is an 
umbrella term that includes sustained attention, response inhibition, working memory, 
error processing and other complex cognitive abilities.4 It is a system that acts in a 
supervisory capacity, is located in the frontal lobes and coordinates complex behavior 
through planning, decision-making, and response control for purposeful goal-directed 
behavior.5, 6 A recent study using a cluster analysis approach showed that executive 
dysfunction was the most prominent cognitive function in HIV neurocognitive 
impairment and most likely to affect behavior.7 
 Genetic association studies have revealed statistical correlations between genetic 
polymorphisms in the dopamine system and measures in executive function.8-11 Similarly, 
there is increasing evidence also implicating the 5-HT system but its role in cognition is 
less clear.12, 13,14 Behavioral studies have demonstrated that serotonin provides a tonic 
inhibition to dopamine facilitatory effects related to several behaviors.15, 16 Similarly, 
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monoaminergic neurotransmitters, including dopamine and serotonin, may interact within 
cortical networks to modulate the expression of specific cognitive functions.17 For 
example, studies on tryptophan depletion have proposed that 5-HT has a strong 
neuromodulatory influence over the orbito-frontal-limbic network associated with 
executive functions.18-20  
 The most widely studied genes of the serotonergic pathway are the tryptophan 
hydroxylase isoform 2 (TPH2) and the serotonin transport gene (SLC6A4).21, 22  
SLC6A4 encodes the serotonin transporter that affects serotonergic neurotransmission by 
reuptake of synaptic serotonin, ending neurotransmission.23 Serotonin reuptake variation 
is linked to a functional polymorphism in the promoter region of the SLC6A4 gene on 
chromosome 17q11.1-q12.23 Polymorphisms within SLC6A4 have influenced memory 
regulation, decision making, and response inhibition capabilities.14, 24, 25 In addition, twin 
studies have shown an additive genetic influence on measures of sustained attention.26, 27  
 The TPH2 gene encodes a member of the protein-dependent aromatic acid 
hydroxylase family.12 It is the rate-limiting enzyme of 5-HT synthesis in the brain, which 
transforms tryptophan into 5-hydroxy-tryptophan, the direct precursor of 5-HT.28, 29 The 
functional SNP rs4570625 is found within the transcriptional region of TPH2 on 
chromosome 12p21.1.12 Evidence of TPH2 variations playing a role in cognition comes 
from studies implicating TPH2 in the pathophysiology of ADHD and obsessive-
compulsive disorder.30-32  Several studies have shown that the homozygous TT genotype 
in SNP rs4570625 is associated with poorer executive control compared to GG and GT 
genotypes.12, 25 Another study showed a similar association using the NoGo- 
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anteriorization test, which is an index of prefrontal functioning.33 These studies showed a 
compensatory adjustment of deficits in executive control functions.28, 33 
 Another gene of interest is galactose mutarotase (GALM). A genome wide 
association study (GWAS) found a strong association between thalamic and a coding 
SNP rs6741892 in GALM using the tracer [11C]DASB-BPND, used to measure brain 
serotonin transporter levels. 34 The study demonstrated that SNP rs6741892 accounted for 
about 50% of the variance in [11C]DASB-BPND binding potential in the thalamus, 
especially for the TT genotype.34  GALM catalyzes the conversion of beta-D-galactose to 
alpha D-galactose, which may affect regional neurophysiology, leading to local increases 
in serotonin release in the brain.35 
 HIV-infected individuals continue to experience neurocognitive deterioration 
despite virologically successful treatment.1 Currently, demographic characteristics and 
medical comorbidities are used to identify individuals who are at risk for HAND.36 Still 
the variance in HAND is not completely explained by these factors. Thus, additional 
characteristics, such as genetic factors associated to HAND susceptibility, should also be 
investigated.37 Genetically determined polymorphisms in serotonin-related genes may 
amplify differences in cognitive performance measures in individuals already with 
impaired cognition. Thus, it was hypothesized that serotonin-related genetic 
polymorphism SLC6A4 5-HTTLPR, TPH2 rs4570625 and GALM rs6741892 are 
associated with impaired executive control and memory. We used a number of cognitive 
measures reported to be valid and reliable measures.38, 39 
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C. Methods 
1. Sample 
This study used baseline data gathered between 2009 and 2012 as part of a longitudinal 
randomized controlled trial for HIV-infected adults who abuse alcohol and other drugs. 
The main study recruited a total of 379 individuals. However, the current study used 267 
biologically-unrelated individuals, because112 participants declined to provide blood for 
genetic testing. Participants were between 18 and 60 years of age, HIV-positive, with a 
history of drinking alcohol in the last three months, and/or a history of alcohol abuse or 
dependence in the past two years. An additional inclusion criterion was not showing overt 
signs of a major psychiatric disorder including psychosis or suicidality. Institutional 
Review Board (IRB) approval was obtained at Florida International University prior to 
the start of the study. After full explanation of the study, written informed consent was 
obtained from all participants.  
2. Genotyping 
 DNA was extracted from whole blood by manual extraction using the QIAamp 
DNA Mini Kit (Valencia, CA). Genotyping for TPH2 and GALM SNPs was conducted 
using TaqMan® SNP Genotyping Assays (Foster City, CA) on Bio-Rad CFX96™ real-
time PCR instrument (Hercules CA). Polymerase Chain Reaction (PCR) amplifications 
were performed by using the Probes Supermix, a 2X reaction buffer which contains the 
necessary components for running PCR. PCR amplifications were performed using the 
manufacturer's suggestion of 20μl total volume and with the following PCR thermal 
cycling conditions: enzyme activation at 95ᴼC for two minutes, and 49 cycles of 
denaturation at 95ᴼC for 5 seconds followed by annealing and extension at 61ᴼC for 5 
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seconds. For the promoter variant called 5-HTTLPR, Bio-Rad CFX Manager software 
(version 3.0) was used for data acquisition and genotype assignment. The primer 
sequences used for the 5-HTTLPR amplification were obtained from a previous study.35 
The sequences were as follow 5’-CCGCTCTGAATGCCAGCACCTAAC-3’ (forward 
primer) and AGAGGGACTGAGCTGGACAACCAC-3’ (reverse primer) amplifying a 
522-bp for the 16-repeat allele and a 478-bp- for the 14-repeat allele35. The 25 μl reaction 
mixture contained: 1 x PCR amplification buffer (Qiagen, Valencia, CA), 300 μM 
dNTPs, 0.5 μM of each primer, 0.5 U Taq DNA polymerase (Qiagen) and 50ng of 
genomic DNA. The temperature cycle consisted of an initial denaturation at 94 ᴼC for 3 
min, followed by 30 cycles of 30 s at 94 ᴼC, 30 s at 60 ᴼC and 30 s at 72 ᴼC, and final 
extension for 2 min at 72 ᴼC. PCR products were separated on a 1.5% agarose gel 
supplemented with gel red and visualized under UV light. All genotypings were 
performed blindly, without knowing the clinical status or any background data on the 
samples.  
3. Neurocognitive Assessment 
 All participants were assessed on the same battery of neurocognitive tests and in 
the same order. Verbal memory and retrieval efficiency were measured with the AVLT, 
using the version World Health Organization/University of California Los Angeles 
(WHO/UCLA).40 Executive function was measured with the SCT.39 and cognitive 
flexibility and sustained attention were measured with the CTT Test A & B.41 Alcohol 
use and other drugs of abuse were measured using the TLFB method for accurate recall 
of drug consumption. AUDIT was used to determine patterns of alcohol consumption. 
AUDIT is a 10-item survey that measures alcohol consumption, dependence symptoms 
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and personal and social harm reflective of drinking over the past 30 days.42 The AUDIT 
scores are: low-risk level (0 to 7), hazardous level (8 to 15), harmful level (16 to 19) and 
possible dependency ( ≥ 20).42 There are no agreed criteria to measure HIV-associated 
neurocognitive disorders. However, the Frascati criteria have been validated and is 
widely used to classify HIV impairments.43 The Fracasti criteria were used to determine 
cognitive impairment. Therefore, impairment in at least two domains and a cut-off of 
greater than one standard deviation below the mean was used to determine asymptomatic 
neurocognitive impairment 44 (Table 2, chapter 2).  
Auditory Verbal Learning Test 
 The AVLT assessment was based on a five-trial presentation of a 15-noun word 
list (list A) with a presentation rate of one word per second. On completion of trial 5, a 
single word presentation of a 15-noun word interference list (list B) was presented. The 
test measured retention, learning and recognition rates with higher scores representing 
better episodic memory.45, 46 This instrument demonstrates high test-retest reliability, 
with alpha scores ranging from 0.51 to 0.72.47  
Short Category Test  
 The SCT assessment consisted of five booklets, one for each subtest, with 20 
cards per subtest. All of the cards within each subtest were organized according to a 
single principle. The test required the individual to formulate an organizing concept for 
each subtest. The number of errors on each booklet was added to determine impairment  
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with lower scores representing better executive function.39 Test-retest coefficients range  
from 0.60 to 0.96, depending upon the severity of impairment in the sample.48 
Color Trail Test 
 Color Trail A and B were presented. Trail A required the individual to connect 
colored circles numbered 1-25 as fast as possible using a pencil. All odd-numbered 
circles had a pink background while all even-numbered circles had a yellow 
background.49 Trail B required the individual to start with a pink colored number one 
circle and alternate between pink and yellow colored circles numbered 2-25 as fast as 
possible. The test measured time to completion, errors, near misses and prompts.49 Trail 
A evaluated sustained visual attention while Trial B evaluated cognitive flexibility.41 The 
test used the raw time in seconds with higher scores indicating poorer functioning.41 This 
instrument demonstrates high test-retest reliability, with alpha scores ranging from 0.85 
to 1.00.41 
D. Analysis 
 Statistical analyses were performed using Stata v.11 (StataCorp, College Station, 
TX). Data were evaluated for potential selection bias since one hundred and twelve 
participants did not participate. To standardize cognitive measures for this study, 
standardized T-scores were developed by using multiple linear regression methods 
analyzing the influence of age, sex, education, and ethnicity on each cognitive test score. 
Each of the five cognitive domains was included as dependent variables: memory 
(recognition measures form AVLT), executive function (number of errors on the SCT), 
sustained attention and cognitive flexibility (time to complete the task for CTT A & B).  
The continuous predictor was age, and categorical predictors were sex, education and 
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race/ethnicity. All the predictors in the model were included in each regression, retaining 
only the variables that significantly contributed to the prediction of cognitive test score. 
These predictive scores were subtracted from each individual's actual composite score to 
calculate residual scores. Finally, residual scores were converted to T-scores (mean = 50 
and SD =10) which were used to determine cognitive impairment.  
 Logistic regression methods were used to calculate crude and adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs). All statistical tests were two-tailed, and the 
threshold for statistical significance was set at P <.05. The ORs, with 95% CIs, were used 
as a measure of effect size. Genotyping counts were tested for Hardy-Weinberg 
equilibrium (HWE) for each SNP. Ethnic and gender-specific associations were assessed 
through stratified analyses. Associations in the overall sample were assessed by adjusting 
for sex and ethnicity/race. By default, the additive genetic model was used, but due to 
previous associations in the recessive model for SCL6A4, the recessive and dominant 
models were also used.  
E. Results 
 A total of 267 HIV-infected alcohol abusers completed the study. Table 1 
provides participant characteristics. The majority of the participants were men 173 
(65%). Ethnicity was self-identified: 203 (76%) were African Americans, 21 (8%) 
Caucasians and 43 (16%) Hispanics. The average age of participants was mean = 45.1 
(SD = 7.1). The majority 190 (69%) completed high school.  HIV disease markers, 
including viral load and CD4 count, were not associated with AIDS diagnosis. About 128 
(48%) of the participants had undetectable viral load, and a CD4 count average was 441.4 
cells/mm3 (SD = 287). Lifetime alcohol use, on average, was 23.8 years in this sample.  
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The mean AUDIT score was 16, and 101(38%) scored > 20. The most commonly used 
drugs besides alcohol were cocaine and marijuana. However, the number of times these 
drugs were used was negligible compared to alcohol use. Selection bias was not observed 
since the nested study was comparable to the main study. The Frascati criteria were used 
to measure neurocognitive impairment. A total of 112 (43%) participants scored below 
the mean (T-score: mean = 50; SD = 10). Asymptomatic neurocognitive impairment, 
greater than one standard deviation below the mean, was observed in 101 (91%) and mild 
neurocognitive impairment, greater than two standard deviations below the mean was 
seen in 11 (9%). Executive function and memory showed the highest impairment in this 
sample (executive function: mean = 58.2 SD = 10.9; Memory: mean = 40.0 SD = 9.1). 
HIV-associated dementia was not observed.  
 Genotyping results, including genotype frequencies are presented in Tables 2 and 
3. All SNPs were in Hardy-Weinberg equilibrium. Analyses yielded significant 
associations with executive function and TPH2 and memory and GALM genetic 
polymorphisms. Whereas, 5-HTTLPR polymorphism did not show an association with 
cognitive flexibility as previously suggested.52 The SNP rs4570625 of TPH2 gene 
showed an overall association in the dominant model with impaired executive function 
(odds ratio = 2.5, 95% CI, 1.1-4.9; p =.02). Furthermore, the association showed an 
increased risk in males (odds ratio = 4.0, 95% CI, 1.6-10.5; p= .007), not in females 
(Pinteraction = .08 for sex). Greater risk was observed in African American males (odds 
ratio 4.8, 95% CI, 1.5-14.8; p = .005). For the SNP rs6741892 of the GALM gene, a 
significant association with impaired memory (odds ratio = 1.9, 95% CI, 1.2-3.1;             
p =.006) was observed. The risk again was increased in African American males (odds 
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ratio 2.4, 95% CI, 1.2-4.9; p =.02). Results from this study showed that the associations 
between serotonin-genes and asymptomatic neurocognitive impairment are male-specific. 
The interaction between GALM and THP2 polymorphisms with alcohol use was non-
significant (p = .65). 
F. Discussion 
 This study provides further evidence for the role of 5-HT in cognition, where 
functional polymorphisms of two candidate genes in the serotonergic signaling pathway 
influence executive function and memory. Significant associations were found between 
TPH2 SNP rs4570625 and executive dysfunction and GALM SNP rs6741892 and 
impaired memory.  Stratification by potential effect modifiers (sex and race) showed an 
even greater effect in African American males but not in females. For the polymorphism 
5-HTTLPR, no statistically significant associations were found with neurocognitive 
measures. Data suggest that the 5-HTTLPR polymorphism is probably not a risk factor 
for cognitive impairment and supports previous studies that reported no association 
between this polymorphism and cognitive abilities or cognitive decline.50, 51 However, 
other studies provided evidence of the influence of 5-HTTLPR polymorphism on 
executive function. For example, a study by Rosier and colleagues evaluated the effect of 
5-HTTLPR polymorphism on executive function in ecstasy users and found a significant 
association with the S allele.52 Another study, observed impaired executive performance 
for homozygous SS genotype compared to LL and LS genotypes in patients affected by 
schizophrenia.21 
 The findings in this study indicate that homozygous TT genotype in SNP 
rs4570625 showed higher error rates measured by the SCT than TG and GG genotypes 
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implicating executive dysfunction. These findings parallel and extend those of functional 
imaging and molecular genetic studies suggesting that polymorphism rs4570625 is a risk 
marker for executive dysfunction. 12, 28, 30 SNP rs4570625 affects the transcription rate of 
TPH2, which may increase the activity of PFC.53  The PFC plays a central role in top-
down control of many higher-order executive tasks.54-56 Evidence from a functional 
image study showed a significant association between SNP rs4570625 and increased 
activity in several prefrontal and parietal sites during updating of working memory.28  
The authors suggested that the effect of SNP rs4570625 was not specific for attention, 
impulse control, or working memory, rather it seemed to reflect one common basal 
cognitive process.28 Another study showed a similar association using the NoGo-
anteriorization test, which is an index of prefrontal functioning.33 These studies showed a 
compensatory adjustment of deficits in executive control functions.33,28 Similarly, results 
in this study are in line with studies suggesting increased PFC activity due to serotonin 
dysregulation affecting executive function.21, 25, 57, 58 Thus, associating executive 
dysfunction to a wide range of behaviors. 
 Behavioral studies have demonstrated that executive dysfunction (i.e., poor 
learning) are central to HIV-neurocognitive impairment and most likely affects 
behaviors, including adherence to antiretroviral medication and unemployment (or 
underemployment).2 Heaton and colleagues found that medically asymptomatic HIV-
infected adults with executive dysfunction were twice as likely to be unemployed and 
perceived greater vocational difficulties than their unimpaired counterparts.59 Similarly, 
another study showed that, for recently diagnosed individuals, the key predictors for 
finding employment were learning and memory.60 
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 This study is the first to analyze the functionality of this SNP rs6741892 in 
relation to 5-HT transporter. Thus, a significant association between rs6741892 and 
memory measured by AVLT was found in HIV-infected alcohol abusers. The AVLT was 
used because the repeated presentations of words and their successive testing at various 
time intervals allowed for the analysis of different learning processes such as acquisition, 
retention, retrieval, and interference.45 The thalamus plays a significant role in regulating 
higher-level brain activity.61 The dorsomedial nucleus is of particular interest because of 
its established role in memory and its extensive reciprocal connections with the PFC.62 
Impaired explicit memory in HIV-infected adults is associated with decreased volumes of 
the thalamus.63 Thus, results in this study showed a significant association with decreased 
total learning, as a measure of explicit memory.  Explicit memory is further divided into 
semantic and episodic memory (Figure 1, Chapter 1). Semantic and episodic memory 
have been associated with neurocognitive deficit in HIV-infected adults.64 Episodic 
memory impairment has been associated with limited use of higher level encoding 
strategies, such as semantic clustering and strategic retrieval.64 This can lead to issues 
involving medication non-adherence and problematic work-related issues in HIV-infected 
adults.65, 66  
 This study has several limitations that should be noted. First, there was relatively 
low frequency of homozygous TT genotype of the TPH2 SNP. However, it should be 
noted that there is relatively low occurrence of TT genotype within the general 
population. In fact, compared to previous studies, the current study included a rather high 
proportion of homozygous TT genotype carriers compared to others.12, 13, 53 Second, the 
lack of alpha-level corrections due to multiple comparisons. However, multiple 
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comparisons were necessary due to the exploratory nature of the study, including the 
analysis of the SNP functionality in the GALM gene, as well as the use of all three genetic 
models.  
 In general the additive model is used to assess statistical associations of SNPs. 
While the additive model has sufficient power to detect associations in most situations, 
there may be occasions where statistical significance is not found, when in fact, there is 
an association. Consequently, a strength in this study was the use of multiple genetic 
models to determine associations that may remain undetectable by the exclusive use of 
the additive model.  
G. Conclusion 
 The current study was the first to explore the relationship between serotonin-
related polymorphisms and asymptomatic neurocognitive impairment in a sample of 
HIV-infected alcohol abusers. The results showed a significant association between 
TPH2 rs4570625 and individual differences in executive function and GALM rs6741892 
with memory. The two associations were male-specific. The present study validates 
previous results pointing to genetic influences on executive function and memory. 
Moreover, a significant association between SNP rs6741892 with memory was 
demonstrated, which may imply SNP rs6741892 as a functional polymorphism in the 
GALM gene affecting 5-TH transport.   
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Table 1. Demographic and clinical characteristics of main and current study participants 
   
Baseline characteristics Main study Current study P values 
 n = 112 N = 267  
Age mean (DS) 44.1 (7.7) 45.1(7.1) .66 
Sex, No (%)   .72 
Male 67 (60) 173 (65)  
Female 45 (40) 94 (34)  
Education No (%)   .24 
8th grade or less 13 (12) 19 (7)  
High school diploma 73 (65) 190 (69)  
Some college 26 (23) 57 (24)  
Race/Ethnicity No (%)   .26 
Caucasian 17 (15) 21 (8)  
African-American 80 (72) 203 (76)  
Hispanic 15 (13) 43 (16)  
Alcohol use mean (DS)    
Number of standard drinks  
(past 90 days) 100 (50.1) 190 (100.1) .10 
Lifetime 22 (10.5) 23.8 (10.9) .24 
AUDIT score 14 (7.5) 16 (8.0) .09 
Other drugs, mean (DS)    
Number of times cocaine use  
(past 90 days) 23.5 (16.8) 33.5 (19.8) .25 
Number of times marijuana use 
(past 90 days) 19.3 (12.5) 25.6 (20.9) .63 
HIV Characteristics mean 
(DS)    
CD4 count 412.9 (318.4) 441.4 (286.9) .73 
Viral load No (%)   .16 
Undetectable 45 (40) 128 (48)  
50-10,000 39 (35) 80 (30)  
10,001 - 30,000 8 (7) 29 (11)  
30,000 or more 20 (18) 29 (11)  
Taking ART 76 (68) 216 (81) .84 
Cognitive measures, mean 
(DS)    
Executive skills T-scores 50.1 (9.0) 48.2 (10.9) .93 
Memory  skills (learning) T-
scores 45.9 (10.1) 48.2 (9.1) .18 
Memory skills (recall) T-scores 48.1 (9.8) 40.0 (10.5) .11 
Cognitive flexibility T-scores 40.4 (10.4) 45.7 (10.8) .09 
Sustained attention T-scores 53.9 (9.3) 56.0 (9.8) .10 
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Table 2. Genotype frequencies and cognitive scores for AVLT and SCT tests 
Genes SNP Genotype N (%) Cognitive T-scores Mean (SD) 
TPH2 rs4570625 AA 93 (36%) 63.2 (10.1) 
 
AB 120 (46%) 59.5 (13.3) 
BB 47 (18%) 57.6 (15.1) 
GALM rs6741892 AA 90 (35%) 50.1 (10.2) 
 
AB 114 (43%) 47.1 (9.0) 
BB 60 (22%) 47.4 (9.8) 
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Table 3. TPH2 and GALM associations with cognitive impairment stratified by sex and race/ethnicity  
(ORs and 95% CIs)   
 
aChromosomal locations are based on the Genome Reference Consortium.  bAlleles are based on Genome Reference Consortium. cORs adjusted for 
alcohol use, CD4 cell count, adherence to antiretroviral medication, sex and self-reported race/ethnicity. dORstratafied by sex  eORstratified by race. fORstrafied by 
sex and race. 
Chr., chromosome; OR, odds ratio; CI confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chra Position  Gene Variant Allele
b Domain Alleles Sexd Racee Sex-Racef 
12 12:71938143 TPH2 rs4570625 G >T Executive function 2.5 (1.1 to 4.9)
 4.0 (1.6 to 10.5) 3.3 (1.4 to 7.6) 4.8 (1.5 to 14.8) 
      P = 0.02 P = 0.01 P = 0.007 P = 0.005 
2 2:38689828 GALM rs6741892 A >T Memory 1.9 (1.2 to 3.1) 2.3 (1.2 to 4.2) 1.9 (1.1 to 3.6) 2.4 (1.2 to 4.9) 
      P = 0.006  P  = 0.009 P = 0.02 P = 0.02 
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CHAPTER IV 
DRD2 AND DRD4 GENES RELATED TO COGNITIVE DEFICITS IN HIV-
INFECTED ADULTS WHO ABUSE ALCOHOL  
 
A. Abstract 
 HIV-infected individuals continue to experience neurocognitive deterioration 
despite virologically successful treatments. There is evidence suggesting that 
neurocognitive impairment is heritable and individual differences in executive function 
and memory are strongly driven by genetic variations. The contribution of genetic 
variants affecting the metabolism and activity of dopamine may influence these 
individual differences. The present study investigated the influence of two candidate 
dopaminergic gene polymorphisms (DRD4 and DRD2) on executive function and 
memory. They were measured by the Short Category (SCT), Color Trail (CTT) and Rey-
Osterrieth Complex Figure Tests (ROCT). Participants were an ethnically diverse sample 
of 267 HIV-infected adults that were genotyped for polymorphisms in the DRD4 48bp-
variable number tandem repeat (VNTR), DRD2 rs6277 and ANKK1 rs1800497. Results 
showed significant associations with the SNP rs6277 and impaired executive function 
(odds ratio = 3.6, 95% CI, 2.4-8.7; p = .001) and cognitive flexibility (odds ratio = 1.7, 
95% CI, 1.3-2.6; p = .01). The results were further stratified by race and sex and 
significant results were seen in males (odds ratio = 3.5, 95% CI, 1.5-5.5; p = .008) and in 
African Americans (odds ratio = 3.1, 95% CI, 2.3-3.5; p = .01). In addition, DRD4 VNTR 
7-allele was significantly associated with executive dysfunction. Specifically, the 7-
absent group performed worse than the 7-present group, in total errors committed in the 
SCT. Results support the notion that dopaminergic variations influence differences in 
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cognition and contribute to an understanding of the relation between genes and cognitive 
impairments in HIV-infection.  
B. Introduction 
 Human immunodeficiency virus (HIV) is a global epidemic that affects 
approximately 36 million people worldwide.1 In addition to its deleterious effects on the 
cell-mediated  immune system, HIV  can also damage cells in the central nervous system 
and lead to HIV-associated neurocognitive disorders (HAND).2 The manifestations of 
HAND have significantly changed in response to the introduction to antiretroviral 
therapy (ART). For example, the incidence of HIV-associated dementia has declined. 
However, the prevalence for asymptomatic and mild neurocognitive impairment have 
increased with increased longevity.3 HAND encompasses a  range of cognitive 
impairment that includes deficient memory and attention, decreased executive function, 
and behavioral changes, such as apathy or lethargy.4  
 Dopamine is a neurotransmitter that regulates functional network activities in 
various regions of the brain.5 Dopamine neurons are located in the ventral midbrain and 
are involved in several cognitive functions that influence performance, motor control, 
reward, and cognition.5-7 Studies investigating the relationship between HIV infection 
and brain pathology have revealed that the HIV virus can cause damage to dopamine-rich 
areas including the basal ganglia, substantia nigra, and the frontal cortex.8-10 For example, 
a neuroimaging study measured basal ganglia volume using magnetic resonance imaging 
reported selective basal ganglia atrophy in adults with HIV-associated neurocognitive 
disorder compared to their HIV-negative counterparts.11 Another study using the same 
method showed that atrophy of the caudate nucleus was significantly associated with 
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cognitive impairment in asymptomatic HIV-infected adults compared to the seronegative 
control group.12 
  Dopamine receptors, D1, D2, D3, and D4 modulate the excitability of receptor 
cells and prefrontal neural network activity.13 The SNP rs1800497 (also known as TaqIA) 
of the D2 receptor gene DRD2 is one of the most extensively investigated genes in 
reference to neuropsychiatric disorders.13, 14 This DRD2-associated polymorphism is 
located within the coding region of a neighboring gene, ANKK1, and is associated with a 
reduced number of dopamine binding sites in the brain.15 The SNP rs1800497 is located 
more than ten kilobase-pairs downstream from the coding region of the DRD2 gene in 
chromosome 11q23 and is, therefore, unlikely to alter DRD2 directly.16 Proximity of the 
two genes may reflect functional relationship and may be associated with dopaminergic 
phenotypes by being in linkage disequilibrium.17, 18 Polymorphism DRD2 SNP rs6277 
has been reported to affect D2 receptor density in the striatum.19 Several studies have 
shown that SNP rs6277 is associated with prefrontal cortex mediated behaviors including 
attentional control, planning and verbal reasoning.14 A study on cognitive flexibility 
showed that SNP rs6277 was a strong predictor for learning from negative reward 
prediction errors by avoiding those responses linked to negative outcomes.17, 20  
 The dopamine D4 receptor is widely expressed in the CNS, particularly in the 
frontal cortex, hippocampus, amygdala and hypothalamus.5, 21 The dopamine D4 receptor 
DRD4 gene is located on chromosome 11p15.5 and has a highly variable number of 
tandem repeats in the coding sequence.22 The polymorphism is a 48bp VNTR sequence in 
exon 3, encoding the third intracellular loop of D4 receptor.23 The most common 
polymorphic variants of the receptor are D4.7, and D4.4.24, 25 Individuals with D4.7 
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repeat show both reduced binding affinities and receptor densities for dopamine 
neurotransmission.26 The D4.7 repeat is correlated with impulsivity and lower levels of 
response inhibition.27 Several studies have analyzed the association between the D4.7-
repeat allele in DRD4 gene and attention-deficit hyperactivity disorder (ADHD).21, 28  The 
present study explores potential associations with DRD2 rs6277, ANNK1 rs1800497 and 
DRD4 48bp VNTR polymorphism and cognitive functions in HIV-infected alcohol 
abusers.     
C. Methods 
1. Participants 
 This study utilized a cross-sectional design, using baseline data gathered between 
2009 and 2012 as part of a longitudinal randomized controlled trial for reducing risk 
behaviors among HIV-infected alcohol abusers. Recruitment was made in densely 
populated, multicultural, low income, urban areas of Miami-Dade County, Florida. 
Participants were between 18 and 60 years of age, HIV-positive and willing to present 
documentation to confirm serostatus, consumed alcohol  within the last 3 months, with a 
history of alcohol abuse or dependence within the past 2 years, and, at the time of 
recruitment, were not showing overt signs of major psychiatric disorders. Additionally, 
availability to provide blood specimen was required. All participants provided signed 
informed consent as approved by the Institutional Review Board (IRB) at Florida 
International University.  
 Participants were evaluated for alcohol use by the Timeline Followback (TLFB) 
and the Alcohol Use Disorders Identification Test (AUDIT) test. All participants were 
assessed using  the same battery of neurocognitive tests and in the same order. Nonverbal 
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memory was measured with the RCFT. Cognitive flexibility and sustained visual 
attention was measured with the CTT test A & B, and executive function was measured 
with the SCT.  
 2. Genotyping 
 DNA was extracted from whole blood by manual extraction using the QIAamp 
DNA Mini Kit (Valencia, CA). SNPs rs6277 and rs1800497 were genotyped using the 
TaqMan® SNP Genotyping Assays (Foster City, CA). Allelic discrimination analysis 
was performed on the Bio-Rad CFX96™ real-time PCR machine (Hercules CA). 
 For VNTR D4, Bio-Rad CFX Manager software (version 3.0) was used for data 
acquisition and genotype assignment. The primer sequences used for the D4 
amplification were obtained from a previous study.29 The sequence was as follows:  
5'CTGCTGCTCTACTGGGC 3' sense and 5'GTGCACCACGAAGGAAGG 3' antisense 
The 25 μl reaction mixture contained: 1 x PCR amplification buffer (Qiagen, Valencia, 
CA), 300 μM dNTPs, 0.5 μM of each primer, 0.5 U Taq DNA polymerase (Qiagen) and 
50ng of genomic DNA. The temperature cycle consisted of an initial denaturation at 94 
ᴼC for 5 min, followed by 30 cycles of annealing for 40 s at 54 ᴼC, extension for 40 s at 
72 ᴼC, denaturing for 40s at 94ᴼC, and then the final extension for 6 min at 72 ᴼC. The 
amplification products were separated on a 3% agarose gel electrophoresis according to 
the number of repeats. The size of the amplified fragments was from 500 bp to 750 bp (2-
7 copies of the 48pb repeat). These genetic markers were chosen based on prior evidence 
of the SNPs conferring risk to neurocognitive deficits or a theoretical association with 
executive function. 
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3. Neurocognitive measures 
The neurocognitive test battery included standardized measures of multiple domains of 
cognitive function selected for their sensitivity to HIV-associated neurocognitive 
impairment. The neurocognitive tests were assessed in the following domains: 
1.  Visual Memory-Rey-Osterrieth Complex Figure Test evaluated 
visuospatial construction and nonverbal memory.30 It consists of a 
complex geometric figure that is copied and then redrawn from memory.31 
Copy and accuracy of correctly copied or recalled elements was measured 
based on a score from 0 to 36. The figure was divided into 18 components. 
Each piece was evaluated with respect to its drawing accuracy with higher 
scores indicating better accuracy. High test-retest reliability scores 0.88 
for copy and 0.87 for recall 31 
2. Sustained attention- Color Trail Test part A evaluated sustained   
 attention.32  Trail A required the individual to connect colored circles  
 numbered 1-25 as fast as possible using a pencil. All odd-numbered circles 
 had a pink background, while all even-numbered circles had a yellow  
 background.33 The test measured time in seconds to complete with higher  
 scores indicating poor performance. High test-retest reliability, scores  
 ranging from 0.85 to1.00.32  
3. Cognitive flexibility- Color Trail Test part B evaluated cognitive 
flexibility. Participants were presented with numbered colored circles that 
required to start with a pink colored number one circle and alternate 
between pink and yellow colored circles as fast as possible.32 The test 
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measured time in seconds to complete with higher scores indicating poor 
performance. High test-retest reliability scores ranging from 0.85 to 
1.00.32 
 4. Executive function-The Short Category Test evaluated executive function.  
  It consisted of five booklets with 20 cards per subtest and required the  
  individual to formulate an organizing concept for each subtest.34 The  
  number of errors on each booklet was added and the total number of errors 
  determined impairment with lower scores representing better executive  
  function.35 Test-retest coefficients range from 0.60 to 0.96 depending upon 
  the severity of impairment in the sample.34 
 
The neurocognitive tests were completed at baseline. Trained personnel administered the 
tests in the same order and according to standardized procedures.  
4. Alcohol Use 
 The TLFB method assessed alcohol use and other drugs of abuse. This method 
obtains estimates of substance use by using a calendar format and providing retrospective 
estimates of the participant's substance use over the last three months.36 The AUDIT is a 
screening tool that is sensitive to early detection of high-risk drinking behaviors as shown 
in Table 1.37  
D. Analysis 
 Since 112 (29%) individuals chose not to participate in this study, data were 
evaluated for potential selection bias. Statistical analyses were performed using Stata 
v.11 (StataCorp, College Station, TX). Logistic regression and linear regression analyses 
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were used to explore the association between dopamine-related genes and cognitive 
impairment (executive functioning, cognitive flexibility and visual memory). The 
statistical threshold was set at P < 0.05 and 95% confidence intervals (CIs). Ethnic and 
gender -specific associations were calculated through stratified analyses. Genotyping 
counts were tested for HWE for each SNP. For the DRD4 polymorphism, the Pearson's 
X2 and t-test were used to compare group differences. For DRD4 48 bp VNTR, alleles 
were grouped in short (S; < 7 repeat) and long (L; ≥ 7 repeat) as described in previous 
studies.38, 39 For statistical analysis, participants were placed in one of two genotype 
groups 7-allele present (homozygous for the short allele) or 7-allele absent (heterozygous 
or homozygous for the long allele).  
 To standardize cognitive measures for this study, standardized T-scores were 
developed by using multiple linear regression methods analyzing the influence of age, 
sex, education, and ethnicity on each cognitive test score. Each of the cognitive domains 
was included as dependent variables. The continuous predictor was age, and the 
categorical predictors were sex, education and race/ethnicity. For each regression, all the 
predictors were included in the model, retaining only the variables that significantly 
contributed to the prediction of cognitive test score. The β weights of each of these 
predictors in the final model, as well as the standard error of each regression model, were 
used to calculate predicted scores on each test. These predictive scores were subtracted 
from each individual actual composite score to calculate residual scores. Residual scores 
were then converted to T-scores (mean = 50; SD = 10). T-scores were used to determine 
cognitive impairment according to the Frascati criteria.40 For the cognitive domains,  
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scores were developed as follows: executive function (SCT), visual memory (RCFT) 
sustained attention (CTT A) and cognitive flexibility (CTT B). 
E. Results 
 Of the 379 participants recruited for the main study, 70% (N = 267) provided 
blood samples. The participants were 94 (34%) females and 173 (65%) males. The 
average age in the sample was: (males: mean = 45.1 SD = 7.1; females: mean = 45.3 SD 
= 65.9). The majority of participants self-identified as African-American 203 (76%), 
followed by Hispanic 43(16%) and Caucasian 21 (8%). A total of 190 (69%) had 
completed high school. At baseline, participants provided recent (within one month from 
intake) lab tests of CD4 count and viral load.  Lab reports showed viral load as 
undetectable for 128 (48%) of the sample and an average CD4 count of 440 cells/mm3 
(SD = 287). The overwhelming majority of participants, 219 (81%) reported currently 
taking antiretroviral medication. Selection bias was not observed when participants’ 
characteristics in the main study were compared to those in the present study. Results 
demonstrated that the participants were similar in age, education, sex, ethnicity and HIV 
clinical characteristics as shown in Table 2.  
1. Alcohol and other drugs of abuse 
 The TLFB determined alcohol and other drugs use. Questions included a total 
number of standard drinks consumed in the last 90 days, the total number of heavy 
drinking days (< 5standard drinks) in the last 90 days, and lifetime alcohol use. A 
standard drink is defined as 12 oz of beer, 5 oz of wine, 1.5 oz of liquor all of which 
contain approximately 13.6 g of absolute alcohol.41 Results showed a mean AUDIT score 
of 16, which is categorized as a harmful drinking level. In addition, a total of 101 (38%) 
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of the participants scored > 20 which is indicative of possible alcohol dependence. 
Lifetime alcohol use averaged 23.8 years for this sample. Additional detailed information 
on other substance use was also assessed. The main drugs used, besides alcohol, were 
cocaine and marijuana, with an average use in the last 90 days of 33 and 25 times, 
respectively. 
 The Frascati criteria were used to measure asymptomatic neurocognitive 
impairment, (1 standard deviation below the mean in at least 2 cognitive domains). 
Results for the neurocognitive measures were below average (T-score: mean = 50 SD = 
10) with the exception of sustained attention (mean = 56.0, SD = 9.8). The cognitive 
domains with the lowest average scores were cognitive flexibility (mean = 45.7; SD = 
10.8) and executive function, with the lowest scores representing better cognition (mean 
= 58.2; SD = 10.9).  
2. DRD2 polymorphism and cognitive flexibility 
 Results of the analyses are presented in Tables 3 and 4. All SNPs were in Hardy-
Weinberg equilibrium. The SNP rs6277 of DRD2 gene showed an overall association 
with impaired cognitive flexibility (odds ratio = 1.7, 95% CI, 1.3-2.6; p = .01) and with 
executive function (odds ratio = 3.6, 95% CI, 2.4-8.7; p = .001). The association between 
SNP rs1800497 and cognitive flexibility was non-significant. Results were stratified by 
sex and race for cognitive flexibility and executive function. Testing show an increased 
risk for executive function impairment in African Americans (odds ratio = 3.1, 95% CI, 
2.3-3.5; p = .001), and an even greater risk for males (odds ratio = 3.5, 95% CI, 1.5-5.5; p 
= .008). There was, a significant gender interaction for cognitive flexibility (pinteraction = 
0.013 for sex), but not for executive function (pinteraction = .35 for sex). Interaction with 
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alcohol was not significant (p = .32) and no significant gene-gene interactions for DRD4 
and DRD2 were found (results not shown).  
3. DRD4 48bp VNTR polymorphism and executive function 
 The allele frequencies for DRD4 48bp VNTR were similar to those observed in 
African populations in other studies.42, 43 In this study, the most frequently detected 
alleles of the 48bp VNTR of the D4 receptor were for DRD4-allele 4 (353/484, 72.9%), 
and DRD4-allele 7 (66/484, 13.7%). To a lesser degree DRD4-allele 2 (38/484, 7.8%), 
DRD4-allele 3 (7/484, 1.5%), DRD4-allele 5 (11/484, 2.3%), and DRD4-allele 6 (9/484, 
1.8%) were also present. The nine and ten repeat alleles were not detected in this study 
population. The genotype distribution of the 242 participants is shown in Table 5. One 
hundred and eighty-six participants were grouped into the 7-absent allele group (< 7 
repeats), and 56 were grouped into the 7-present allele group (≥7 repeats). When 
comparing allele groups, the 7-allele present and 7-allele absent groups did not differ in 
sex, race/ethnicity, alcohol use, or CD4 count. The 7-absent allele group mean score was 
associated with a higher rate of error in SCT measuring executive function than the 7-
present group (mean: 0.17, 95% CI 1.17-1.29; p = 0.008). In addition, a multiple linear 
regression with executive function as the dependent variable and age, sex, alcohol use, 
genotype group and race/ethnicity as the independent variables showed that DRD4 7-
absent allele and age had a significant effect on executive function. Whereas, sex, alcohol 
use and race/ethnicity did not show a significant effect (data not shown). 
F. Discussion 
 This study provided evidence that suggests genetically determined differences in 
DRD2 gene polymorphism (rs6277) and in the DRD4 gene (48 VNTR) are associated 
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with impaired executive function and cognitive flexibility. However, no associations 
were found with SNP rs1800497. It is well-recognized that genes are likely to affect more 
than one cognitive function, and variations in cognitive functions are likely to be 
influenced by more than one gene.44 Similarly, this study showed that the DRD2, SNP 
rs6277 is associated with impairment in two cognitive domains: executive function and 
cognitive flexibility. Conversely, executive function is influenced by DRD2 and DRD4 
genetic polymorphisms. Although recent publications stress the need to consider gene-
gene interactions, our results showed no such interactions.44  
 The present study found a significant association between DRD2 genetic 
polymorphisms and executive dysfunction and impaired cognitive flexibility. The study 
showed that SNP rs6277 CC homozygous genotype was less efficient in inhibitory 
control as it took them more time to complete the task than TT and CT genotypes. 
Results of this study are consistent with those that reported an association between CC 
genotype and poorer working memory performance and executive functioning.45, 46,32  
However, results are mixed in the literature regarding the precise influence of the 
SNP rs6277 DRD2 on distinct cognitive processes and the effect's direction 
respectively.47  For example, one study showed that high circulate DRD2 binding 
potential in the TT genotype was associated with a higher rate of error in the Wisconsin 
Card Sorting Test, measuring executive function.48 Conversely, Colzato and colleagues 
reported lower inhibitory control in SNP rs6277 CC homozygous genotype, which was 
associated with lower levels of DRD2 striatal dopamine availability.49 This incongruence 
may be explained by a recent analysis on the regional specificity of SNP rs6277 in the 
DRD2 gene.50 The DRD2 genotypes lead to differences in binding affinities and 
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availabilities in striatal versus extrastriatal regions.50 In all extrastriatal regions the CC 
genotype is associated with the highest DRD2 binding potential, whereas the CC 
genotype is associated with the lowest binding potential in the striatum.51 Thus, the SNP 
rs6277 in the DRD2 gene changes the receptor's affinity and regulates DRD2 availability, 
but its effect differs depending on the brain region under investigation.50, 51 Neuroimaging 
studies suggest that the functional SNP rs6277 is associated with DRD2 density changes 
across the cortex and thalamus.50 For example, a meta-analysis showed a significant 
association between the SNP rs6277, C allele and schizophrenia.52 Furthermore, studies 
have proposed that higher cortical DRD2 density is a risk factor for executive dysfunction 
as shown for schizophrenia.19, 53, 54 Thus, our results suggest that higher cortical DRD2 
density may also be considered a risk factor for HIV-associated neurocognitive 
impairment.  
 The DRD4 48bp VNTR polymorphism has been previously linked to ADHD 
phenotypes.28, 55-58 In particular, the specific allele (7-repeat) of the 48pb VNTR 
polymorphism in the coding region of DRD4 may be a risk factor for the development of 
ADHD.28 ADHD is known to alter prefrontal cognitive functions that are often related to 
dopaminergic dysfunction. 59 Thus, following previous studies on ADHD, this study 
sought to assess whether cognitive functions (cognitive flexibility and executive function) 
were associated with the DRD4 48bp VNTR polymorphism in HIV-infected adults. 
Results in this study showed that the 7- absent allele group was significantly associated 
with executive dysfunction. The effect of the DRD4 VNTR on executive function 
reported herein is comparable with a familial study that reported a significant association 
between the 7-absent allele group and lower scores in working memory and executive 
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function.55 Similarly, several studies on DRD4 VNTR showed that DRD4 7-absent allele 
group was associated with worse cognitive functioning than the DRD4 7-present allele 
group.57, 60 However, the results of this study conflicts with the findings of other similar 
studies. One study found poorer inhibitory performance in the 7-present allele group 
versus the 7-absent allele group.56 Another, found that 7-present allele group performed 
better that the 7-absent allele group on verbal memory, but for visuo-constructive ability 
(WAIS-III Block Design ) and set shifting (WCST) the 7-absent allele group performed 
better than the 7-present allele group.61  
 This poses important questions with respect to the relationship between genetic 
risk and neurocognitive performance. There are several potential explanations for these 
conflicting results. First, higher and lower than average levels of synaptic dopamine may 
lead to neurocognitive impairment.62 This is a particularly interesting since the 7-present 
allele is associated with reduced receptor functioning.61 Second, the combinations of 
certain risk genotypes rather than one single risk genotype may lead to the presence of 
cognitive dysfunction.63 Third, Boontra and colleagues suggested that the investigation of 
haplotypes rather than genotypes may yield stronger associations.61 These relationships 
have not been fully tested and required further research, especially since cognitive 
endophenotypes are important for HIV-associated neurocognitive impairments.  
 Due to the exploratory nature of the study, multiple statistical comparisons were 
made. Because of the low power of the study to detect smaller effect sizes, some 
important associations may not have emerged as statistical significant. These results 
should be viewed with caution and should be replicated before definitive conclusion can 
be drawn. Alternatively, these results can serve as an initial point for future research in 
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cognitive phenotypes for HAND in adults. Molecular genetics, as applied in the present 
study, offers further analytic insight of the analysis besides behavioral assessment and 
neuroimaging, and may present a reasonable instrument for the dissociation of different 
executive control processes. Since most of the polymorphisms have a relative small effect 
on cognition, to detect an effect, a larger sample is optimal. In addition to the genes 
analyzed in this study, other genes related to cognitive function should be included in the 
future.    
 In summary, the present study provides evidence that genetically determined 
differences in the SNP rs6277 DRD2 gene and DRD4 48bp VNTR may be a risk factors 
for executive function and cognitive flexibility deficits. Furthermore, rs6277 showed an 
association with impairment in two cognitive domains (executive function and cognitive 
flexibility) while executive function seems to be influenced by DRD2 and DRD4 genetic 
polymorphisms. Finally, DRD4 48bp VNTR (7-allele absent group) was associated with 
executive dysfunction, which is in line with the recent proposal that either higher or 
lower levels of synaptic dopamine may lead to neurocognitive impairment. 
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Table 1. Alcohol Use Disorders Identification Test (AUDIT) scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significance of Scores 
0 -7 Low risk of alcohol-related harm 
8-10 High risk of experiencing alcohol-related harm 
11-19 Already experiencing significant alcohol-related harm 
20+ 
Possible alcohol dependent advisable further testing to 
determine dependence. 
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Table 2. Demographic and clinical characteristics of main study and current study  
participants 
  
 
 
 
 
Demographic Characteristics Main study Current study P values 
 n = 112 N = 267  
Age, mean (DS) 44.1 (7.7) 45.1(7.1) .66 
Sex, No (%)   .72 
Male 67 (60) 173 (65)  
Female 45 (40) 94 (34)  
Education No (%)   .24 
8th grade or less 13 (12) 19 (7)  
High school diploma 73 (65) 190 (69)  
Some college 26 (23) 57 (24)  
Race/Ethnicity No (%)   .26 
Caucasian 17 (15) 21 (8)  
African-American 80 (72) 203 (76)  
Hispanic 15 (13) 43 (16)  
Alcohol use, mean (DS)    
Number of standard drinks  
(past 90 days) 100 (50.1) 190 (100.1) .10 
Lifetime 22 (10.5) 23.8 (10.9) .24 
AUDIT score 14 (7.5) 16 (8.0) .09 
Other drugs, mean (DS)    
Number of times cocaine use  
(past 90 days) 23.5 (16.8) 33.5 (19.8) .25 
Number of times marijuana use 
(past 90 days) 19.3 (12.5) 25.6 (20.9) .63 
HIV Characteristics, mean (DS)    
CD4 count 412.9 (318.4) 441.4 (286.9) .73 
Viral load No (%)   .16 
undetectable 45 (40) 128 (48)  
50-10,000 39 (35) 80 (30)  
10,001 - 30,000 8 (7) 29 (11)  
30,000 or more 20 (18) 29 (11)  
Taking ART 76 (68) 216 (81) .84 
Cognitive measures, mean (DS)    
Executive skills T-scores 50.1 (9.0) 48.2 (10.9) .93 
Memory  skills (learning) T-scores 45.9 (10.1) 48.2 (9.1) .18 
Memory skills (recall) T-scores 48.1 (9.8) 40.0 (10.5) .11 
Cognitive flexibility T-scores 40.4 (10.4) 45.7 (10.8) .09 
Sustained attention T-scores 53.9 (9.3) 56.0 (9.8) .10 
Visual Memory T-scores 47.9 (11.9) 43.1 (13.8) .09 
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           Table 3. DRD2 and ANKK1 associations with cognitive domains  
 
Chr. Positiona Gene Variant Allelesb Domain OR (CI%) 
11 11:113412737 DRD2 rs6277 C/T Cognitive flexibility 1.7 (1.3 to 2.6) 
      p = .01 
11 11:113412737 DRD2 rs6277 C/T Executive function 3.6 (2.4 to 8.7) 
      p = .001 
11 11:113400106 ANKK1 rs1800497 C/T Cognitive flexibility 1.1 (0.7 to 1.8) 
      p = .71 
 
 
Table 4. DRD2 associations with cognitive flexibility and executive function              
by gender, race/ethnicity groups and alcohol use (ORs and 95% CIs) 
 
 
 
  
 
Females Males Hispanics African American Alcohol Use 
DRD2 rs6277 
(executive 
function) 
1.3 
3.5 
(1.5 to 5.5) 
p = .008 
2.6 
3.1 
(2.3 to 3.5) 
p = .01 
2.6 
 
 pinteraction = .35 pinteraction = .05   
DRD2 rs6277 
(cognitive 
flexibility) 
0.9 
 
1.8 
(1.2 to 2.9) 
p =.01 
 
1.9 
 
1.5 
 
1.6 
(1.4 to 2.4) 
p =.03 
 pinteraction = .013 pinteraction =.72 pinteraction = .32 
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                Table 5.  D4 Receptor 48bp repeat genotype group classification 
 
 
                 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
  
 
             
     Group 1: 7-absent group: < 7-fold repeat of the 48bp repeat of D4 receptor 
       Group 2: 7-present group: ≥ 7-fold repeat of the 48bp repeat of D4 receptor 
 
 
 
 
 
 
 
 
 
 
 
 
  
D4 receptor 48bp 
repeat genotype N % 
Genotype 
group 
2/2 8 3.3 1 
2/3 2 0.8 1 
2/4 20 8.4 1 
3/4 2 0.8 1 
3/6 3 1.0 1 
4/4 140 57.8 1 
4/5 5 2.0 1 
4/6 6 2.6 1 
4/7 40 16.7 2 
5/7 6 2.4 2 
7/7 10 4.2 2 
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CHAPTER V 
 
 
A RANDOMIZED CONTROL TRIAL OF A MANUAL-GUIDED RISK REDUCTION 
INTERVENTION FOR HIV-INFECTED ALCOHOL ABUSING INDIVIDUALS 
 
A. Abstract 
 
 Improved HIV treatments and decreased mortality from AIDS-related illness have 
been paralleled by increased prevalence of HIV infection.  HIV infection transmission 
risk is compounded by alcohol abuse and related risky sexual behaviors. Interventions 
that target alcohol use are central to improving the health of HIV-infected alcohol 
abusers. This study randomized 284 HIV-infected alcohol abusers to either the adapted 
Holistic Health Recovery Program (HHRP-A) or the Health Promotion Comparison 
program (HPC). Overall HIV sexual transmission risk behaviors decreased in both the 
experimental HHRP-A and HPC control groups. Cognitive impairment was measured as 
a moderator for alcohol use. Results showed that impaired cognitive flexibility and visual 
memory were associated with increased alcohol use. (F = 1, 3.82, η2 = 0.03, p = .05;, and 
F = 1, 5.79, η2 = .05 p = .02) respectively. At the six-month follow-up, HHRP-A 
participants were less likely to report trading sex for food, drugs and money (20.0%) and 
unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex (3.2%) than 
HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04). The number of times 
that sex was traded for food, money and drugs decreased in men in the HHRP-A 
experimental group (food: Z = 2.2  p = .03; money: Z 3.4  p = .001; drugs: Z = 3.1 p 
=.002). Similarly, men and women exhibited decreases in the number of episodes of sex 
following alcohol consumption (men: Z = 2.0 p = .04; women: Z = 2.3 p = .02). This 
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study suggests that HHRP-A is an effective intervention program for the reduction of 
sexual transmission risk behaviors in HIV-infected alcohol abusers. 
B. Introduction 
 
 The reduction of HIV transmission risk behaviors among HIV-infected 
individuals remains a major health priority. Depression, substance use, and stressful, 
traumatic experiences have been identified as predictors of sexual transmission risk.1, 2 
The impact of heavy alcohol use in HIV-infected individuals has not been extensively 
examined.3, 4 Approximately 5% of the total US population abuses alcohol. However, the 
prevalence of alcohol abuse in HIV-infected individuals is between 30 to 60%.5, 6  HIV-
infected alcohol abusers are more prone to rapidly progressing illness with higher viral 
loads, increased immune suppression, and cognitive impairments compared to HIV-
infected alcohol non-abusers.3  Behavioral factors associated with alcohol abuse can also 
increase HIV disease progression, interfering with antiretroviral therapy adherence.4 
Alcohol consumption impairs judgment and cognition which diminishes risk perception, 
therefore increasing HIV risk transmission.7 Over 70% of people infected with HIV 
remain sexually active after diagnosis and one-third engages in unprotected sexual 
behavior.8   
 An area of recent interest is on the interaction between alcohol and HIV on 
cognition. Regular daily consumption of six or seven standard alcoholic drinks may be 
associated with moderate cognitive impairment.9 On the other hand, individuals affected 
by both alcohol abuse and HIV infection may suffer a compounded deficit in cognitive 
performance which may affect adherence to antiretroviral medication and treatment 
outcomes.10 Clinical research shows that not all chronic drinkers are equally at risk for 
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brain changes; most suffered mild cognitive impairment that improved within a year of 
abstinence.11, 12  
 A study reported high rates of knowledge on how to prevent HIV transmission 
among infected persons, but uncertainty about how to make these changes was a factor 
for not changing their behavior.13 Efforts to reduce risk of HIV transmission and alcohol 
abuse have been guided by several models of health behavior change.14 One theoretical 
approach that has effectively predicted HIV-related health behaviors in diverse samples is 
the Information-Motivation-Behavioral Skills (IMB) model.15, 16 The model states that 
HIV prevention information and motivation work through preventive behavioral skills to 
influence risk reduction behaviors.17 The Holistic Health Recovery Program (HHRP) is 
an evidence-based intervention guided by the IMB model for HIV-infected drug users.18 
The HHRP-A is an adapted version of the HHRP program designed for alcohol abusers 
based on the IMB model. The HHRP-A is a manual-guided intervention designed to 
reduce sexual transmission risk and alcohol use in HIV-infected alcohol abusers.19 In 
addition, the HHRP-A incorporated cognitive remediation strategies by using materials 
and techniques that minimize the effects of cognitive difficulties. This study evaluated 
the effectiveness of the IMB-based, manual-guided intervention using HHRP-A to reduce 
sexual transmission risk and alcohol use in HIV-infected alcohol abusers.   
C. Methods 
1. Sample 
 A total of 284 HIV-infected adults were recruited from CBOs in Miami, Florida, 
between January 2009 and November 2012. The slow recruitment process was planned to 
help reduce treatment group cross-contamination and group assignment bias. The 
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inclusion criteria for the participants were age between 18 and 60 years, HIV-positive and 
willing to present documentation to confirm serostatus, alcohol consumption within the 
last three months and/or a history of alcohol abuse or dependency within the past two 
years, and at least one episode of unprotected vaginal or anal sex in the past 90 days. 
Additional criteria included:  ability to understand and speak English, understand and 
give informed consent, provide contact information for follow-up interviews, willingness 
to be randomized to the experimental or control group, not facing immediate 
incarceration or residence in a restricted environment, and no evidence of major 
psychiatric disorders. The Institutional Review Board of Florida International University 
approved the research protocol, and all participants provided signed informed consent 
prior to participating in the study. 
2. Neurocognitive Assessment 
 The following tests measured neurocognitive deficits at baseline. 1) The Short 
CategoryTest- measured executive function by abstract concept formation and learning,20 
2) The Rey-Osterrieth Complex Figure Test-measured visual memory,21 3) The Auditory 
Verbal Learning Test-measured retention rates, learning rates and recognition,22, 23 4) The 
Color Trail Test part A-measured sustained attention,24 and 5) The Color Trail Test part 
B-measured cognitive flexibility.24 The Frascati criteria were used to measure 
impairment.25  
3. Study Design 
 This study was a prospective randomized clinical trial where participants were 
assigned to the experimental or control groups. Participants were entered into the study in 
cohorts of eight of the same gender. Cohorts were assigned to receive either the 
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experimental or control condition according to a computer-generated random sequence. 
The random sequencing controlled for bias in subject assignments across conditions. The 
experimental group used the HHRP-A intervention program designed to promote risk 
reduction behaviors among HIV-infected alcohol abusers.26 The HHRP-A intervention 
manual was highly structured and involved both didactic presentations of material as well 
as experiential exercises. Participants attended eight sessions lasting two hours, twice a 
week, for four weeks. The intervention addressed harm reduction skills training, relapse 
prevention and reduction in HIV sexual transmission risk behaviors. Each session was 
co-facilitated by two counselors using a nonjudgmental, motivational enhancing 
therapeutic style. Cognitive remediation strategies were incorporated because of the 
potential for cognitive impairment in this population. Some of these strategies included 
emphasis on structure and consistency, repetition and review, behavioral games and 
memory books, as well as ongoing assessment of new learning and retention, with 
immediate provision of feedback. 
 The Health Promotion Comparison (HPC) group focused on educational and 
didactic methodologies, addressing common health problems such as nutrition, physical 
fitness, and healthy living. The HPC did not incorporate behavioral skills training or 
motivational enhancement techniques. The HPC matched HHRP-A in total 
administration time and format (eight, two-hour sessions). However, the program was 
condensed and delivered in two days to reduce the risk of cross-group contamination and 
the potential for enhancing social support that group sessions repeated over time could 
engender. A standard care HIV education component was included in the HPC because it 
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was considered ethically irresponsible not to include HIV education in a comparison 
condition, given the high-risk nature of this population.  
 Assessments were conducted at baseline and six-month follow-up. The timeline 
follow-back (TLFB) method was used to measure alcohol use and sexual transmission 
risk behaviors. TLFB uses a calendar format that provides retrospective estimates of the 
participant's substance use and sexual conduct over the last 90 days.27 Alcohol abuse was 
defined by the amount consumed (e.g., at risk, heavy) or by the consequence of its use 
(e.g., abuse, dependence).4 Alcohol abuse is defined by the National Institute on Alcohol 
Abuse and Alcoholism (NIAAA) as > 4 drinks on an occasion or >14 drinks in a week 
for men, and > 3 and > 7 for women, respectively.28 In addition, computer assisted 
personal interview, and audio computer assisted self-interview were used for baseline 
data. Data were collected at baseline and six-month follow-up for all measures. 
Participants were offered incentives for participation as follows: $50 gift card to local 
stores upon completing the baseline data collection; $25 gift card upon completing post-
intervention assessments; $15 cash or gift card for attendance at each group session; and 
$5 cash for transportation. 
4. Outcome Measures 
 At the baseline and six-month follow-up assessments, participants reported on 
alcohol use and sexual transmission risk behaviors. The number of vaginal, anal and oral 
sex events without a barrier and times participant traded sex for food, money, or drugs, 
and number of sex events directly following alcohol consumption were used to measure 
sexual transmission risk.  The number of drinking days, heavy drinking days (≥ 5 
standard drinks), and the number of standard drinks were used to measure alcohol use. 
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Report of any or no incident of trading sex for food, drugs and money, sex directly 
following alcohol consumption, unprotected insertive or receptive oral, anal or vaginal 
sex were compared as categorical variables at six-month follow-up by group assignment 
(HHRP-A versus HPC).  Hazard ratios (HRs) were calculated as measures of relative 
risk; 95% confidence intervals and p-values from Chi-square or Fisher’s exact 2-tailed 
tests were used for significance testing.   
 Analyses were conducted with SPSS version 20 (IBM, 2011). Continuous 
measures were quantities consumed or frequency of alcohol use and sexual transmission 
risk events. Data for alcohol use were transformed using the Box-Cox method,29 and 
sexual transmission risk used nonparametric methods. Initially, the Wilcoxon signed-rank 
test was used for all the analyses. Transformed data were analyzed using the t-test and 
ANOVA methods to measure the outcomes. Change over time on continuous measures 
was analyzed using two repeated measures by analyses of variance (ANOVAs) for 
treatment condition and time variables. Where change over time in any continuous 
variable was detected, effect sizes (partial η2) were reported. The intervention outcomes 
were assessed by alcohol use measured by total number of standard drinks in the last 90 
days and the total number of heavy drinking days (≥ 5 standard drinks) in the last 90 
days. Sexual transmission risk was measured by number of insertive and receptive anal or 
vaginal sex events without a condom, number of episodes receiving or giving oral sex 
without a barrier, number of times the participant traded sex for food, drugs and money, 
and number of sex events directly following alcohol consumption. The outcomes were 
modeled as a function of condition (intervention or control), time (baseline and follow-
up), gender, and condition by time. The interaction between neurocognitive measures and 
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alcohol was also measured in both conditions.  Cognitive impairment was measured by 
normalized T-scores in this sample.  Normalized T-scores were developed by using 
multiple linear regression methods analyzing the influence of age, sex, education, and 
ethnicity on each cognitive domain. The normalized T-scores (mean = 50 and SD =10) 
were used to determine cognitive impairment.  
D. Results 
 A total of 284 participants were randomized to either the control group 140 
(49.3%) or the experimental group 144 (50.7%). There was no significant difference 
between the groups in age, or gender (Table 1). The predominant race for both groups 
was African American (control group: 71%; the experimental group: 72%). They did not 
differ significantly by ART use and immunologic or virologic status. Demographic, 
behavioral and clinical characteristics for the control and experimental groups are 
presented in Table 1. According to Frascati criteria a total of 109 (41%) of the 
participants in the sample scored below the mean, in the domains of executive function, 
cognitive flexibility and memory (T-score: mean = 50; SD =10). Asymptomatic 
neurocognitive impairment, greater than one standard deviation below the mean was 
observed in 98 (90%) of these individuals, and mild neurocognitive impairment, greater 
than two standard deviations below the mean was observed in 11 (10%). (Frascati 
definition Table 3, Chapter 2). The proportion with neurocognitive impairment at 
baseline did not differ significantly between the two groups.  
1. Alcohol use 
 Analyses of the intervention impact on the outcomes for alcohol consumption 
revealed an overall significant decrease in alcohol consumption by time (F = 3, 162, η2 = 
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0.54, P = <.01) for the experimental and the control groups, but there were no significant 
differences between experimental and control groups in alcohol use reduction. When 
cognitive impairment was measured as a moderator for alcohol use. Results showed that 
impaired cognitive flexibility and visual memory were associated with increased alcohol 
use. (F = 1, 3.82, η2 = 0.03, p = .05; and F = 1, 5.79, η2 = .05 p = .02), respectively. 
2. Sexual transmission risk 
 Proportions of study participants who reported HIV risk behaviors at six-month 
follow-up differed by intervention group assignment; in all cases, participants in the 
experimental condition had better risk reduction outcomes. At baseline trading sex for 
food, drugs or money and number of sex events directly following alcohol consumption 
were the most frequent HIV risk behaviors reported. At the six-month follow-up, HHRP-
A participants were less likely to report trading sex for food, drugs and money (20.0%) 
and unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex (3.2%) than 
HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04) shown in Table 2. 
Additionally, a significant decrease for trading sex for food, money and drugs (food: Z = 
2.2 p = .03; money: Z 3.4 p = .001; and drugs: Z = 3.1 p = .002), as well as decreased 
number for vaginal sex events without a barrier (Z = 1.9 p = .05) was observed over time 
in study participation, which was statistically significant only in men. Both men and 
women had similar statistically significant decreases in number of reported sex events 
directly following alcohol consumption (men: Z = 2.0 p = .04; women: Z = 2.3 p = .02). 
No significant changes for number of anal or oral sex events without a barrier were 
reported. The control group showed a small decrease in trading sex for food, money or 
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drugs, sex following alcohol consumption. However, this decrease was not significant as 
shown in Table 3. 
3. Attrition analysis 
 Of the 278 participants who completed the baseline assessment, 185 (66%) also 
completed the six-month follow-up assessment. Of the 94 (34%) participants who did not 
complete the follow-up assessment, three died, one went to jail, and 90 were excluded 
from the analyses due to incomplete data and/or were lost to follow-up. Some of the 
reasons for loss to follow-up included seeking health care at another clinic and not 
returning to complete the assessment for unknown reasons. No difference (p > .35) in 
attrition was seen by study condition, demographic factors, or baseline sexual 
transmission risk behaviors (vaginal, anal and oral sex without a barrier, trading sex for 
food, money, or drugs, and number of sexual events after alcohol use) or for alcohol use 
(total number of standard drinks in the last 90 days and total number of heavy drinking 
days in the last 90 days). 
E. Discussion 
 The study evaluated the efficacy of the HHRP-A intervention program and 
showed a significantly lower level of HIV transmission risk behaviors at the six-month 
follow-up assessment in the experimental compared to the control group. Proportions 
reporting sexual transmission risk behaviors including trading sex for food, money, or 
drugs and unprotected sex were 49% to 80% lower six months post-intervention among 
HHRP-A participants versus comparison group members. Additionally, alcohol use 
decreased for number of heavy drinking days (≥ 5 standard drinks) and total number of 
standard drinks in both the intervention and control groups.  
98 
 
Alcohol abuse has been associated with increased involvement in sexual risk 
behaviors, including sex under the influence, trading sex for drugs or money, and vaginal 
and/or anal sex events.30  Very few HIV intervention programs address alcohol abuse as 
part of their intervention; our results are encouraging in that respect.31-34 In addition, a 
significant interaction effect was found between alcohol use and cognitive impairment in 
the domains of cognitive flexibility and visual memory which were associated with 
increased alcohol use. These results are similar to clinical studies showing that alcohol 
abuse is associated with impairments in specific neuropsychological functions.12 
However, some studies have suggested an increase in vulnerability to cognitive 
impairment due to the interaction between chronic alcohol use and HIV infection.35, 36  
For example, one study examined the effect of current heavy alcohol use and HIV 
infection on cognitive performance and found a synergistic effect for the heaviest current 
drinkers (> 6 drinks per occasion) and HIV infection on motor and visuomotor speed.37 
Individuals affected by both alcohol dependency and HIV infection may suffer 
compounded deficit in cognitive performance which may affect ART adherence and 
treatment outcomes.10 The results in this study showed a similar trend of lower 
functioning in cognitive areas affected by both alcohol and HIV infection. 
 Alcohol use may not only interfere with prevention strategies, but may threaten 
the success of emerging biomedical approaches to HIV prevention.4, 38, 39  Behavioral 
interventions such as HHRP-A specifically tailored for HIV-infected alcohol abusers are 
necessary for this  population. To our knowledge this is the first HIV intervention study 
that demonstrated specific reductions in sexual transmission risk behaviors in HIV-
infected alcohol abusers. The current study also provided important information about 
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which sexual transmission risk behaviors are most common among HIV-positive alcohol 
abusers. These behaviors include trading sex for money and drugs, unprotected sex, and 
sex following alcohol use. These preliminary results showed that HHRP-A is an effective 
intervention for sexual transmission risk-reduction behaviors. However, the highest 
decrease in sexual risk behaviors were observed mostly in men. These results may be 
related to the women's economic dependency on men, as well as  to the men's 
cooperation in decreasing sexual risk behaviors. Thus, it is important to incorporate risk 
reduction behavior strategies that are specifically geared for men and women 
respectively.  
 There were a few limitations in the ability to draw conclusions in this study. First, 
for ethical reasons, the participants who were active in alcohol or drug abuse treatment 
programs could not be excluded. Thus, we were not able to determine the extent to which 
HHRP-A components alone had an impact on alcohol use at the six-month follow-up. 
This is an important issue that should be addressed in the future. Second, although 
significant differences were found for sexual transmission risk behaviors the high loss to 
follow up (34%) limits the interpretability of the findings. Last, alcohol use and sexual 
transmission risk were assessed by self-reports alone allowing for either overestimation 
or underestimation of the number of sexual events or quantity of alcohol consumed.  
 Some of the strengths in this study were the ethnic diversity of the sample and the 
representation of patients with neurocognitive impairment. Second, the HHRP-A 
program covered a range of topics relevant to HIV-infected alcohol abusers and provided 
cognitive remediation strategies to facilitate learning and retention. Moreover, the 
treatment condition was manual-guided, and procedures for assuring the integrity of the 
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treatment conditions were used. Finally, this population was recruited from Miami-Dade 
County, Florida, the metropolitan area with the highest HIV prevalence in the nation: our 
results may be relevant for other highly-impacted urban areas.40 
 In conclusion, findings from this study, although preliminary, suggest that 
enhancing substance abuse treatment with comprehensive interventions that address the 
special needs of HIV-infected alcohol abusers can provide important benefits.  
Implementation of interventions, such as HHRP-A that target individuals already infected 
with HIV appear to be essential to control the spread of HIV. These interventions will 
need to meet the special needs of substance-using HIV-infected population and should be 
incorporated into addiction treatment.  
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 Table 1. Baseline Demographic, behavioral and clinical characteristics of the control and   
experimental groups 
 
 
 
 
 
 
Characteristics Control  n = 140 (%) 
Experimental  
n = 144 (%) P value 
Age in years, mean (SD)* 44.9  (7.5) 45.4 (6.8) .70 
Male 77 (55) 89 (62) .67 
Ethnic background   .43 
Caucasian 13 (9) 20 (14)  
African American 99 (71) 104 (72)  
Hispanic 19 (14) 23 (16)  
Education   .44 
Some college 29 (21) 37 (26)  
High school diploma 53 (38) 48 (33)  
Some school no diploma 58 (41) 59 (41)  
HIV characteristics Mean (SD*)    
CD4+ T-lymphocyte count  469 (303.8) 466 (328.9) .42 
Viral load undetectable  60 (43) 76 (53) .56 
Taking antiretroviral therapy (ART)  100 (71) 114 (79) .24 
Alcohol Use and Sex Behaviors 
Mena (SD*) 
 
   
Lifetime alcohol use years  
 23.5 (11.2) 23.2 (10.8) .88 
Currently in an alcohol treatment 
facility 84 (60) 97 (67) .15 
In the last 12 months in an alcohol 
treatment facility  
 
 
50 (40) 
 
47 (33) .09 
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Table 1. Continued……. 
 
 
 
*SD standard deviation 
 
  
Characteristics Control group n = 140 
Experimental 
group n = 144 P value 
Traded sex for food, drugs or money in 
last 90 days  
 
59/130 (45.3) 54/149 (36.2)   .12 
Had any sexual event directly following 
alcohol consumption in last 90 days  
 
69/117 (59.0) 106/143 (74.1)  .009 
Had insertive or receptive oral sex 
without a barrier in last 90 days 37/132 (28.0) 48/144 (33.3) .34 
Had vaginal and/or anal sex without a 
barrier in last 90 days 
 
25/132 (18.9) 29/144 (20.1) .80 
Cognitive measures, Mean T scores 
(SD*)    
Executive function T-scores  50.1 (10.4) 44.7 (10.1) .001 
Cognitive Flexibility T-scores 46.5 (10.5) 43.2 (10.9) .36 
Sustained attention T-scores 45.5 (10.8) 41.1 (10.2) .29 
Visual memory T-scores 50.5 (10.3) 51.1 (10.3) .44 
Memory T-scores 39.6 (9.1) 39.8 (10.5)  .46 
Proportion with Neurocognitive 
Impairment  
 
49/133 (35%) 
       
60/134 (41%) .19 
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Table 2. HIV risk behaviors at six-month follow-up by assignment  
 
*95%CI 95% Confidence Interval    
 
 
  
All 
HIV Risk Behaviors                       Group 
Number (%) 
Reporting 
Behavior 
Hazard Ratio 
(95%CI)* 
 
P value 
Traded sex for food, drugs and 
money, last 90 days 
Experimental 19/95  (20.0) 0.41  (0.27 to 0.64) 
 
<.001 
 
Control  42/85  (49.4)   
Sex events directly following 
alcohol consumption, last 90 
days 
Experimental 15/106 (14.1)  0.89  (0.43 to 1.8)          .75 
Control 11/ 69 (15.9)   
    
Insertive or receptive  oral sex 
without a barrier, last 90 days 
Experimental 11/95 (11.6) 0.51  (0.26 to 1.0)         .05 
Control 18/80 (22.5)   
Vaginal and anal sex without a 
barrier in last 90 days 
Experimental 3/95 (3.2) 0.2  (0.06 to 0.70)         .04 
Control 12/78 (15.4)   
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     Table 3 HIV risk behaviors at six-month follow-up by assignment and gender  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
                      
                     The effect size was calculated by dividing the Z by the square root of N (r= Z/√N) using the Wilcoxon  Signed-rank Test.  
             *Measures for trade sex for food or money in the control group were not calculated because of the low number of participants. 
 
 
 
 
Measure Intervention Women  Men  
*Traded sex for shelter or food 
last 90 days 
Experimental Z = 1.2   p = .24 
 
Z = 2.2  p = .03   r = 0.31 
Control Z = 0.7   p = .45    
*Traded sex for money last 90 
days 
Experimental Z = 1.2   p = .21 
 
Z = 3.4  p = .001  r = 0.35 
Control   Z = 0.6  p =.56  
Traded sex for drugs last 90 days 
Experimental Z = 0.9   p = .36 
 
Z = 3.1  p = .002  r = 0.25 
Control Z = 0.5   p = .62  Z = 0.9  p = .34  
Sex events directly following 
alcohol consumption last 90 days 
Experimental Z = 2.3  p = .02  r= 0.30 Z = 2.0  p = .04  r = 0.34 
Control Z = 0.9   p = .32  Z = 1.3  p = .20  
Vaginal sex without a barrier last 
90 days 
Experimental Z = 0.9   p = .32  Z = 1.9  p = .05   r = 0.29 
Control Z = 1.5    p = .07  Z = 0.5  p = .61  
Sex events without a barrier last 
90 days 
Experimental Z = 1.5   p = .13 
 
Z = 2.7  p = .008  r = 0.37 
Control Z = 0.7   p = .49  Z = 2.2  p = .02      r = 0.27 
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CHAPTER VI 
 
CONCLUSION 
A. Summary of Conclusions 
 HIV-infected individuals continue to experience neurocognitive deterioration 
despite viral suppression due to successful ART treatment.1  Currently, demographic 
characteristics, and medical comorbidities are used to identify individuals who are at risk 
for HAND.2, 3 However, additional risk factors such as the role of genetics in relation to 
HIV-neurocognitive susceptibility should be investigated.4 Memory deficits, and 
executive dysfunction are highly prevalent among HIV-infected adults. These conditions 
can affect their quality of life, antiretroviral adherence, and HIV risk behaviors.5, 6  
Cognitive functions are influenced by the serotonin and dopamine systems. Thus, genetic 
differences in the serotonin and dopamine system genes may exacerbate the development 
of neurocognitive impairment in an individual.1, 5, 7, 8  The study's overarching hypothesis 
was to determine whether specific genetic differences in HIV-infected alcohol abusers 
were correlated with executive dysfunction, impaired cognitive flexibility and memory, 
and whether these cognitive deficits moderated alcohol use and sexual transmission risk 
behaviors.  
 The third chapter investigated the potential associations between single nucleotide 
polymorphisms in the serotonin system genes and cognitive impairment in HIV-infected 
adults. A total of 267 biologically unrelated individuals were genotyped for 
polymorphisms SLC6A4 5-HTTLPR, TPH2 rs4570625 and GALM rs6741892. The SCT, 
CTT A&B and AVLT tests were used to assess cognitive functions.  Results showed a 
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significant association for TPH2 and GALM variants with executive function and 
memory. This study provided further evidence for the role of serotonin in cognition, 
where TPH2 and GALM gene polymorphisms affect 5-HT signaling pathway influencing 
executive function and memory. These findings parallel and extend those of functional 
imaging studies and molecular genetics suggesting that the TPH2 genetic variant 
rs4570625 is a risk marker for cognitive impairment. 9-11 Moreover, a significant 
association was found between GALM polymorphism and memory, which may imply 
SNP rs6741892 as a functional polymorphism in the GALM gene affecting 5-TH 
transport.12   
 The fourth chapter investigated the influence of two candidate gene 
polymorphisms (DRD4 and DRD2) in the dopamine system. Executive function and 
cognitive flexibility domains were measured by the SCT, CTT A&B and ROCT tests. 
Participants were genotyped for polymorphisms in the DRD4 48bp-variable number 
tandem repeat (VNTR), DRD2 rs6277 and ANKK1 rs1800497. This study found 
significant associations with DRD2 and DRD4 genes and impaired cognition. SNP rs6277 
of the DRD2 gene showed a significant association in two cognitive domains (executive 
function and cognitive flexibility). DRD4 48bp VNTR (7-allele absent group) was 
significantly associated with executive dysfunction, which is in line with a recent 
proposal that either higher or lower levels of synaptic dopamine may lead to 
neurocognitive impairment.13 In summary, these studies suggest a compounded effect of 
genetic influence and HIV infection on cognition in HIV-infected individuals.  
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 The fifth chapter randomized 284 HIV-infected alcohol abusers to either the 
adapted Holistic Health Recovery Program (HHRP-A) or the Health Promotion 
Comparison program (HPC). The HHRP-A is based on the IMB model; it is a manual-
guided intervention designed to reduce sexual transmission risk and alcohol use in HIV-
infected alcohol abusers.14 The intervention phase was evaluated at the six-month follow-
up for sexual transmission risk and alcohol use. Results showed a significant decrease for 
trading sex for food, money and drugs in men but not in women. Additionally, men and 
women exhibited decreased number of sex events following alcohol use. Finally, 
cognitive impairment was measured as a moderator for alcohol use. Results showed that 
impaired cognitive flexibility and visual memory were associated with increased alcohol 
use. This study suggests that HHRP-A is an effective intervention for the reduction of 
sexual transmission risk behaviors in HIV-infected alcohol abusers. 
 Public health genomics is an area of public health  that focuses on the effective 
translation of genomics research into population health benefits. Genomics plays a role in 
most chronic diseases and these chronic diseases are partly the result of how genes 
interact with environmental and behavioral risk factors.16-19 Thus better understanding of 
the genetic interaction with the environment can help not only clinical practitioners 
identify, develop and evaluate screening tools, but this can also help develop 
interventions that can improve health and prevent disease.  
  The evidence for variability in genetic susceptibility to cognitive impairment as 
previously demonstrated has laid the groundwork for an approach to intervention 
development and implementation informed by genomics which may pave the way to a 
more personalized approach to prevention depending on the patient genotype.16 Similarly, 
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the outcomes from this dissertation may provide further understanding of how genetic 
predispositions influence the neuromodulatory serotonin and dopamine systems relevant 
to cognitive impairment and risk behaviors in HIV-infected alcohol abusers. More 
personalized treatments including clinical markers, such as cognitive and genetics tests, 
may not only assist in determining who is more at risk  but, may be able to assist in 
determining the type intervention strategies that can be used when a prevention program 
is developed and implemented. Interventions that target alcohol use is central to improve 
the health of HIV-infected alcohol abusers.15  The HHRP-A intervention program is an 
effective method to reduce sexual transmission risk among HIV-infected alcohol abusers. 
Enhancing substance abuse treatment with this kind of comprehensive intervention that 
addresses the special needs of HIV-infected alcohol abusers is  needed and should be 
further evaluated.  
   This dissertation had two main limitations, first, the lack of alpha-level 
corrections due to the multiple comparisons that were made, however, these comparisons 
were necessary because of the exploratory nature of the studies in this dissertation. Thus, 
results should be view with caution and must be replicated. Second, it was not possible to 
evaluate the efficacy of the HHRP-A intervention for reducing alcohol use due to the 
participants were also active in alcohol or drug abuse treatment programs. Thus, future 
studies should include individuals not currently enrolled in a substance abuse treatment 
program. Similarly, in the future genetic studies on cognition should include, in addition 
to the polymorphisms analyzed in this dissertation, other genes related to cognitive 
function since most of the polymorphisms have relative small effects on cognition. In 
summary, the results in this dissertation can serve as an initial point for future research in 
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cognitive phenotypes for HAND in adults. These findings provide evidence that 
dopamine and serotonin polymorphisms influence executive function and memory as 
well as moderate alcohol use and that HHRP-A was effective in reducing sexual 
transmission risk behaviors in HIV-infected alcohol abusers.    
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 Appendix 2. Community-based organizations assessed by the main study 
 
Name Website 
Borinquen Health Care Center http://www.borinquenhealth.org/ 
Florida Department of Health: 
Broward County Department 
Sexually transmitted Disease 
Program 
http://browardchd.org/default.aspx 
Center for Haitian Coalition http://www.hccinc.org/ 
South Florida Provider Coalition 
Spectrum Programs 
http://www.drugrehabcomparison.com/facility
/florida/miami/spectrum-programs-inc-south-
florida-provider-coalition/ 
The Salvation Army https://donate.salvationarmyusa.org 
Care Resource http://www.careresource.org/ 
Empower U, Inc. http://www.empower-u-miami.org/ 
The Village http://www.villagesouth.com/ 
South Florida AIDS Network http://www.jacksonhealth.org/services-sfan.asp 
The Center for Positive Connections 
Support & Resource Center 
http://www.aidsnet.org/newmain/providers/ce
nterpositive 
South Beach AIDS Project Inc. http://www.miami.com/south-beach-aids-project-inc 
Miami Beach Community Health 
Center, Inc. http://www.miamibeachhealth.org/ 
Helen B. Bentley Family Health 
Center, Inc. 
http://www.helenbbentleyfamilyhealthcenter.c
om/ 
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   Appendix 3. Additional Tables for Methods Section 
 
 
Table 4. Real-time PCR Protocol 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Table 5. Cycling Conditions on CFX96 PCR System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction Setup Per Reaction (μl) 
SsoFast™ Probes Supermix 2X 5.00 
TaqMan® SNP Genotyping Assay 20X 0.50 
DNase-free water 1.50 
Template DNA 3.0 
Cycling Step Temperature Time No. of Cycles 
Denature 95 o C 2 min 1 
Annealing 95 o C 5 sec 
49 X 
Extension 72o C 5 sec 
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Table 6. PCR Protocol 
 
Reaction Setup Per Reaction (μl) 
PCR buffer 10X 2.5 
dNTP mix 1.0 
Primer (forward) 0.5 
Primer (reverse) 0.5 
Taq DNA polymerase 0.5 
DNase-free water 17.0 
Template (DNA) 3.0 
 
 
 
Table 7. Cycling Conditions on MyCycler PCR System 
 
Cycling Step Temperature Time No. of Cycles 
Denature 94o C 30 sec 1 
Annealing 60 o C 30 sec 
30 X 
Extension 72o C 2 min 
Final Extension 72 o C 2 min  
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  Appendix 4. Genetic terminology used in this dissertation 
Term Definition 
Allele A known variation (version) of a particular gene 
Base pair (bp) When quantified refers to the physical length of a sequence 
of nucleotides 
Carrier A healthy person who is a heterozygote for a recessive trait. 
Denaturation Reversible disruption of hydrogen bonds between 
nucleotides converting a double-stranded DNA molecule to 
single-stranded molecules. Heating or strong alkali 
treatment result in denaturation of DNA. 
DNA (deoxyribonucleic 
acid) 
The large double-stranded molecule carrying the genetic 
code. It consists of four bases (adenine, guanine, cytosine 
and thymine), phosphate and ribose. 
Chromosome Structure in a cell nucleus that carries the genes. 
Gene Physical and functional unit of heredity that carries 
information from one generation to the next, which is the 
entire DNA sequence necessary for the synthesis of a 
functional polypeptide or RNA molecule. In addition to the 
coding regions (exons), a gene may have non-coding 
intervening sequences (introns) and transcription-control 
regions 
Genome-wide 
association study 
(GWAS) 
Simultaneous investigation of up to five million genetic 
variants covering the whole genome in complex genetic 
diseases. 
Genotype The diploid genetic formula at one or more loci. 
Genotype-environment 
(GXE) interaction 
This term refers both to the modification of genetic risk 
factors by environmental risk and protective factors and to 
the role of specific genetic risk factors in determining 
individual differences in vulnerability to environmental risk 
factors 
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Hardy-Weinberg 
equilibrium (HWE) 
In an infinitely large population, gene and genotype 
frequencies remain stable as long as there is no selection, 
mutation, or migration. For a bi-allelic locus where the gene 
frequencies are p and q: p2+2pq+q2 = 1.  
 
Linkage Disequilibrium The tendency for two 'alleles' to be present on the same 
chromosome (positive LD), or not to segregate together 
(negative LD). As a result, specific alleles at two different loci 
are found together more or less than expected by chance. The 
same situation may exist for more than two alleles. Its 
magnitude is expressed as the delta (D) value and corresponds 
to the difference between the expected and the observed 
haplotype frequency. 
MAF Minor allele frequency (MAF) refers to the frequency at 
which the least common allele occurs in a given population. 
PCR Polymerase chain reaction. A technique that allows 
amplification of specific DNA segments in a very short time. 
rs Reference SNP ID 
SNP is a single nucleotide change in the DNA sequence code It is 
the most common type of stable genetic variation and is bi-
allelic 
VNTR is a linear arrangement of multiple copies of short repeated 
DNA sequences that vary in length and are highly 
polymorphic, making them useful as markers in genetic 
analysis 
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